1

Prof. Hilal A. Lashuel

Curriculum Vitae

Date: December 16th, 2016

Institution: ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE

Institute: Brain Mind Institute Title: Associate Professor of Life Sciences Lab website: http://lashuel-lab.epfl.ch

2

Date of Birth January 15th, 1973 Citizenship American-USA Education 1994 B.S. City University of New York, Brooklyn College

(Cum Laude in Chemistry) 2000 Ph.D. Texas A&M University/ Scripps Research Institute

Academic Appointments 2011 - present Associate Professor of Life Sciences- Chemical Biology of Neurodegeneration Director of the Laboratory of Molecular and Chemical Biology of Neurodegeneration

Brain Mind Institute, Faculty of Life Sciences, EPFL, Switzerland, http://lashuel-lab.epfl.ch

2014 - 2016 Executive Director, Qatar Biomedical Research Institute (QBRI), Qatar Foundation,

Doha, Qatar. 2012 - 2013 Visiting Associate Professor, Department of Neurology and Neurological Sciences,

Stanford School of Medicine, Stanford University 2005 - 2011 Assistant Professor of Neuroscience- Chemical Biology of Neurodegeneration Director of the Laboratory of Molecular Neurobiology and Functional

Neuroproteomics. Brain Mind Institute, Faculty of Life Sciences, EPFL, Switzerland, 2005 - 2008 Director of the EPFL Proteomic Core Facility- Faculty of Life Science, EPFL,

Switzerland, http://pcf.epfl.ch 2002 - 2004 Instructor of Neurology- Structural basis of amyloid toxicity Harvard Medical School and Brigham and Women’s Hospital, Boston, MA, USA. 2001 - 2002 Sabbatical Fellow- Identification of modulators of Ubiquitin C-terminal Hydrolase

(UCH-L1) activity. Laboratory for Drug Discovery in Neurodegeneration, Harvard Medical School, Boston, MA, USA. Advisor: Prof. Peter T. Lansbury, Jr

2001 - 2002 Postdoctoral Fellow- Mechanism of amyloid formation and toxicity. Center of Neurologic diseases, Brigham and Women’s Hospital and Department of

Neurology, Harvard Medical School, Boston, MA, USA. Advisor: Prof. Peter T. Lansbury, Jr.

2000 - 2001 Research Scientist- Design of mechanism based small molecule inhibitors of amyloid fibril formation. The Picower Institute for Medical Research, Great Neck, NY.

3

1994 - 1999 PhD Student- Organic Synthesis and Biophysics Advisor: Prof. Jeffery W. Kelly Texas A&M University, College Station, TX, and The Scripps Research Institute, La

Jolla, CA. Thesis concerned

“Biophysical studies on the acid denaturation of Transthyretin: understanding the mechanism of amyloid fibril formation in human amyloid diseases”.

“Design, synthesis, and biophysical characterization of peptidomimetic-based model systems for understanding amyloid fibril formation in human neurodegenerative diseases”

1994 - 1997 Teaching Graduate Assistant- Taught an advanced chemistry laboratory in organic

synthesis, purification and structural characterization using NMR, FTIR, GC/MS. Department of Chemistry, Texas A&M University, College Station, TX.

International Boards and Committees 2013 - present Member-Brain Forum Scientific Advisory Board 2011 - present Member-Executive Committee-International Brain Research Organization- IBRO 2015 - present Co-Chair- Scientific Advisory Committee, Qatar BioBank & Qatar Genome Project 2015 - present Co-Chair- Scientific Advisory Committee, Qatar Metabolic Institute 2015 - 03/2016 Member-Path Towards Personalized Medicine (PTPM) Steering Committee Qatar National Research Fund. 2010 - present Founding Member and Member- Executive Committee- International Brain Research Organization-Middle East and North Africa (IRBO-MENA) Chapter 2010 - present Member-Executive Board of the Society for Advancing Science and Technology in the Arab World. 2015 - 03/2016 Chair-Qatar Metabolic Research Group 2015 - 03/2016 Member-Board of Trustees Qatar Biobank and Qatar Genome 2015 - 03/2016 Member-Joint Qatar Foundation-Weil-Cornell Medical College Qatar Advisory Board 2014 - 03/2016 Co-Chair-Qatar Cancer Research Partnership- with Lord Araa Darzi, 2014 - 03/2016 Member- Steering Committee, Academic Health System-Qatar 2014 - 03/2016 Member- Advisory Committee -Department of Health Sciences, Qatar University- Medical School 2014 - 03/2016 Member-Strategic Research Planning Committee, Sidra Medical and Research Center Consultant/Advisor 2015 - present The Brain Forum 2012 - 2013 Michael J Fox Foundation 2008 - 2010 World Economic Forum, Geneva, Switzerland 2007 - 2009 Sidra Medical & Research Center, Doha, Qatar. 2006 - 2009 Qatar Foundation for Education, Science and Community Development, Qatar 1999 - 2000 Warner-Lambert Inc, Park Davis Pharmaceutical, MI, USA. 1999 - 2000 Yamanuchi Pharmaceutical Inc, Japan.

4

Editorial Boards 2011 - present Member, Editorial board of ChemBiochem 2008 - present Associate Editor, Frontiers in Molecular Neuroscience 2007 - 2010 Member, Academic Editorial Board of PLoSONE (http://www.plosone.org) Professional Affiliations o World Economic Forum-Young Global Leaders o American Society for Biochemistry and Molecular Biology o American Chemical Society o American Association for the Advancement of Science o Society for the Advancement of Science and Technology in the Arab World (Co-founder and Board

Member) http://sastaworld.com

5

AWARDS AND ACADEMIC HONORS

2012 Named a Young Global Leader (YGL) by the World Economic Forum: YGLs are nominated in recognition of their record of professional accomplishments, their commitment to society and potential to contribute to shaping the future of the world through your inspiring leadership”” http://www.weforum.org/community/forum-young-global-leaders

2011 EPFL-Section of Life Sciences and Technologies Ambition Award. In recognition for

dedication to the development of student training and enrichment programs, including the summer research program and student senior year annual international trips.

2009 Recipient of the European Research Commission (ERC) Young Investigator Award CHF 2, 245, 200 (Success rate 10%) and ERC Proof of concept Award (2013)

2009 Recipient of the Human Frontiers Science Program Young Investigator Award

($450,000, total amount $750,000, shared with Prof. Ashraf Brik, success rate 10%)

2009 Featured by the Swiss business magazine L'Hebdo among the 2009 "100 outstanding personalities” in the French speaking part of Switzerland" (Forum des 100). The list includes personalities of all horizons that, by their action or their vision, contribute to the dynamism and to the innovation in French-speaking Switzerland. http://www.forumdes100.com/2009/05/100-personnalit%C3%A9s-qui-font-la-suisse-romande-%C3%A9dition-2009.html

2007 Recipient of the critical challenges in Parkinson’s’ disease award from the Michael J Fox Foundation for Parkinson’s Research $400,000

2006 Sana’a University leadership and service award

2006 Taiz University award for distinguished service to research in Yemen

2001 - 2002 Sabbatical Fellowship, Laboratory for Drug Discovery in Neurodegeneration.

Harvard Center for Neurodegeneration and Repair (HCNR)

1997 - 1998 American Chemical Society (Organic Division) Pre-doctoral Fellowship

1997 National Science Foundation, Travel award

1995 Phi Lambda Epsilon, Honorary Chemical Society

1994 Who's Who Among Students in American Colleges and Universities

1994 Sigma Xi Scientific Research Society of North America

1994 Louis Gibofsky Memorial Scholarship in Chemistry

1993 - 1994 Alliance for Minority Participation Scholar (Research Grant)

1993 Mae and Jack Rimmer Scholarship for Excellence in Chemical Research

1993 Golden Key National Honor Society

1992 - 1993 Collegiate Science and Technology Entry Program Research Scholar

1992 - 1994 Undergraduate Research Award in Chemistry

6

Laboratory of Molecular and Chemical Biology of Neurodegeneration Director: Prof. Hilal A. Lashuel Our Mission: To elucidate the molecular mechanisms underlying neurodegeneration in Alzheimer's and Parkinson's disease and develop novel strategies to facilitate the diagnosis, prevention and treatment of these diseases. Research Interest: Research in the Lashuel laboratory focuses on applying integrated chemical, biophysical, and molecular/cellular biology approaches to elucidate the molecular and structural basis of protein misfolding aggregation and pathology spreading and the mechanisms by which these processes contribute to the pathogenesis of neurodegenerative diseases including Parkinson’s disease (PD), Alzheimer’s disease (AD) and Huntington’s disease (HD) and Amytrophic Lateral Sclerosis (ALS). Current research efforts cover the following topics: (1) Elucidating the sequence, molecular and cellular determinants underlying protein aggregation, pathology spreading and toxicity in the central nervous systems (CNS) and enteric nervous system (ENS); (2) developing novel chemical approaches and tools to investigate the role of post-translational modifications in regulating the function/dysfunction of proteins implicated in the pathogenesis of AD (Tau), PD (α-Synuclein), HD and ALS (TDP-43); 3) identification of biomarkers and development of novel imaging agents for early detection, monitoring of disease progression and response to therapies and disease staging; (4) developing novel cellular models to test and validate therapeutic targets, and assess disease modifying strategies based on modulating protein modification, aggregation, pathology spreading and clearance.

7

Our Approach: Our interdisciplinary approach is centered on three major themes. First, we use chemical, biochemical and biophysical tools and methods to elucidate the molecular determinants and mechanisms that govern the misfolding and aggregation of key proteins implicated in the pathogenesis of Alzheimer’s and Parkinson’s disease. Second, our group is applying advances in synthetic chemistry and developing novel chemical methods and tools that allow for the monitoring and control of protein misfolding and aggregation inside and outside the cell with spatial and temporal resolution. These tools and molecular probes are essential for understanding the mechanisms of protein aggregation and its role in neurodegeneration. Third, we use animal models and develop novel cellular models to test our mechanistic models, validate novel therapeutic targets, and assess disease-modifying strategies.

8

Laboratory of Molecular and Chemical Biology of Neurodegeneration Current Group Members Name Position Background Anne-Laure Mahul-Mellier Post-doc Biology-Apoptosis Jean-Christophe Copin Post-doc Biology-Neuroscience John Blaine Warner IV Post-doc Chemical Biology Mahmood Haj Yahya Post-doc Chemistry Niran Maharjan Post-doc Biology Joan Romani Aumedes Post-doc Neuroscience Elena Tobolkina Post-doc Chemistry Andreas Reif Post-doc Chemistry Nadine Ait Bouziad PhD student Neuroscience Sophie Vieweg PhD student Chemistry Anass Chiki PhD student Bioengineering Iness Benmessaoud PhD student Physics Firat Melek Altay PhD student Neuroscience Alexandra Cristina Piloiu Master student Chemistry Technical Staff Driss Boudeffa Research Associate Biology Administrative Assistant Marie Rodriguez Administrative Assistant (80%)

9

\

PUBLICATIONS

1. PUBLICATION AND CITATIONS

2. PUBLICATION BY JOURNAL

3. MANUSCRIPTS UNDER REVIEW OR IN REVISION

4. PUBLISHED ARTICLES

5. REFERRED BOOK CHAPTERS

6. MEETING REPORTS

7. ARTICLES ON SCIENCE AND EDUCATION IN THE MIDDLE EAST

8. PATENTS

10

1. PUBLICATION AND CITATIONS OVERVIEW (source ISI) as of September 2013 ISI web of Knowledge Total number of papers published = 122 ISI Total citations = 8762 h-Index = 48 - Age = 43 Citation per/paper = 65

Google Scholar: Total citations = 11891 h index = 54 i10 index = 104

Published items in each year Citations in each year

Complete List of Publications & Citations

1. Pubmed http://www.ncbi.nlm.nih.gov/pubmed/?term=lashuel

Google Scholar

http://scholar.google.ch/citations?user=tDdAP4EAAAAJ&hl=de&oi=ao

11

2. PUBLICATION BY JOURNAL

Journal Impact Factor

Total/Career (1st/senior author)

Nature 38 2(2) Cell 32.6 1 Nature Review Neuroscience 29.3 1(1) Molecular Cell 14 1 Neuron 14 2 Light: Science and Applications 13.5 1 Nature Structural Biology 13.4 1 Molecular Psychiatry 13 1 J. American Chemical Society (ACS) 13 5(3) J. Clinical Investigation 12.6 1 Genes & Development 12.6 1 Angewandte Chemie. Int. Ed. 11.8 7(4) Nature Protocols 9.6 1(1) PNAS 9.4 7(3) Cell Death and Differentiation 8.2 1(1) Journal of Neuroscience 7.9 3(2) NanoScale 7.8 1 Quarterly Review of Biophysics 7.2 1(1) Organic Letters 6.7 1(1) Chemical Communication 6.6 1(1) Human Molecular Genetics 6 2(2) Molecular and Cellular Proteomics 5.9 1(1) Chemistry and Biology 5.8 1 Medicinal chemistry 5.6 1 ACS Chemical Biology 5.6 2(2) J. Medicinal Chemistry 5.6 1 Molecular Neurodegeneration 5.5 1 FASEB J 5.3 1 Scientific Reports 5.2 1(1) Progress in Brain Research 5.1 1 Neurobiology of Disease 4.9 2(1) J. Molecular Biology 4.5 8(5)

12

ACS Chemical Neuroscience 4.4 1(1) J. Biological Chemistry 4.3 15(13) J. Neurochemistry 3.9 1 FEBS Letters 3.6 2 ChemPhysChem 3.1 1 PLoS One 3 3(2) Protein Science 3 1 Biochemistry 3 8(5) Bioorganic and Medicinal Chemistry 3 1(1) ChemBiochem 2.9 5(3) Biopolymers 2.6 3(2) J. Molecular Neuroscience 2.4 1 Biochem Biophysics and Research Comm 2.4 3(1)

BMC biotechnology 2.4 1 Journal Biomolecular Screening 2.3 1(1) Materials Research Bulletin 2.3 1(1) Amyloid: The Journal of Protein Folding Disorders 2.3 1

Toxicology Research 2.16 1 Neurosciences letter 2.1 1 Advances in Experimental Medicine and Biology 1.9 1

Methods in molecular biology 1.29 2(2)

13

3. MANUSCRIPTS THAT ARE UNDER REVIEW OR REVISION (* Senior and/or corresponding author)

1. El Turk F, De Genst E, Guilliams T, Fauvet B, Hejjaoui M, Vendruscolo M*, Lashuel HA*, Dobson

CM*. “Exploring the role of post-translational modifications in regulating α-synuclein interactions by studying the effects of phosphorylation on nanobody binding”. J. Biol. Chem, 2016, minor revisions requestd- revised version resubmitted

2. Etezadi D, Warner J.B, Ruggeri F.S, Dietler G, Lashuel HA, and Altug H, “Nanoplasmonic Mid-

Infrared biosensor for in-vitro protein secondary structure detection”. Light: Science & Applications, 2016, Accepted with minor revision.

3. Ait-Bouziad N, Lv G, Mahul-Mellier AL, Xiao S, Zorludemir G, Eliezer D, Walz T and Lashuel HA*. “Discovery and Characterization of Novel Stable Tau Oligomeric Complexes: Implications for the Role of Tau/Phospholipid Interactions in Regulating its Functions in Health and Disease” 2016, Nature Communication. Under review

4. DeGuire SM, Ruggeri SM, Fares MF, Cendrowska U, Dietler G, and Lashuel HA*. A Novel Phosphorylation-Dependent Switch of Huntingtin Exon1 Structure, Aggregation and Subcellular Targeting. Hum. Mol. Gene. 2016, Under review.

5. Chiki A., DeGuire SM., Ruggeri SF., Cendrowska U., Ansaloni A., Wang Z., Sanfelice D., Burai R., Vieweg S., Pastore A., Dietler G., and Lashuel HA*. “Huntingtin structure and aggregation is regulated by cross-talk between N-terminal post-translational modifications”. Angewandte Chem. Int. Ed., 2016, Under review.

6. Ruggeri SS, Mahul AL, Kasas S, Lashuel HA, Longo G & Dietler A. “Single Cell Amyloid Toxicity

by Nanomotion Detection”. Nature, 2016, Submitted.

7. Mathur V, Burai R, Vest R, Do D, Mistry KN, Li L, Lashuel HA, Wyss-Coray T. “Ganciclovir suppresses brain inflammation by activating a type I interferon response via STING” Science Translational Medicine, 2016, submitted.

8. Gopaldass N, Fauvet B, Lashuel HA, Roux A, Mayer A. “The PROPPIN Atg18 is a Membrane Scission Protein”, 2016, Nature Cell Biology, Submitted

9. Daldin M, Fodale V, Cariulo C, Azzollini L, Verani M, Martufi P, Spiezia MC, Chiki A, Deguire SM, Cherubini M, Macdonald D, Weiss A, Bresciani A, Vonsattel JB, Petricca L, Marsh JL, Gines S, Iolanda Santimone I, Marano M, Lashuel HA, Squitieri F and Caricasole A. Polyglutamine expansion affects huntingtin’s conformation in multiple Huntington’s disease models. Submitted

10. Cariulo C, Azzollini L, Verani M, Martufi P, Chiki A, Deguire SM, Cherubini M, Gines S, Marsh LJ, Lavery D, Doherty E, Conforti P, Cattaneo E, Santimone J, Squitieri F, Lashuel HA, Petricca L, and Caricasole A. Phosphorylation of huntingtin at residue T3 is decreased in Huntington’s disease and modulates mutant huntingtin protein conformation, PNAS, 2016, Submitted.

11. Ruggeri S, Benedetti F, Lashuel HA, Sekatsky S, Dietler G. “Nanomechanical Manipulation of

Monomeric Assembled Amyloid Protofilaments of alpha-synuclein”, 2015, ACS Nano, In revision

14

12. Miranda HV, Oliveira L, Szegő É, Darendelioglu E, Breda C, Machado de Oliveira R, Ferreira D, António Gomes, M, Oliveira M, Munari F, Enguita F, Simões T, Ferreira Rodrigues E, Heinrich M, Martins IM, Zamolo I, Riess O, Cordeiro C, Ponces-Freire A, Lashuel HA, Santos NC. “Glycation potentiates alpha-synuclein-associated neurodegeneration in synucleinopathies”, 2015, PloS Biology, A revised version is currently under review.

13. Machado de Oliveira R, Miranda H, Francelle L, Pinho R, Munari F, Lázaro DF, Martinho R, Moniot

S, Guerreiro P, Fonseca L, Becker S, Marijanovic Z, Antas P, Szego E, Gerhardt E, Enguita FJ, Penque D, Pais TF, Kügler S, Steegborn C, Zweckstetter M, Lashuel HA, and Outeiro TF. “The mechanism of SIRT2-mediated protection against alpha-synuclein toxicity in models of Parkinson’s disease” 2016, PloS Biology, In revision

4. PUBLISHED ARTICLES Articles in peer reviewed journals (* Senior and/or corresponding author)

1. Awad L, Jejelava N, Lashuel HA*. “A novel caged-glutamine derivative as a tool to control the

assembly of glutamine-containing amyloidogenic peptides”, ChemBioChem, 2016 Oct 27. doi: 10.1002/cbic.201600474. [Epub ahead of print]

2. Dikiy I, Fauvet B, Jovičić A, Mahul-Mellier A, Desorby C, El-Turk F, Gitler AD, Lashuel HA*,

Eliezer D*. Semisynthetic and in vitro phosphorylation of alpha-synuclein at Y39 promotes functional partly-helical membrane-bound states resembling those induced by PD mutations. ACS Chem Biol. 2016 Jul 11. [Epub ahead of print]

3. Ruggeri FS, Vieweg S, Cendrowska U, Longo G, Lashuel HA* and Dietler G*..Nanoscale studies link

amyloid maturity with polyglutamine diseases onset . Scientific Report. 2016,, 6:31155. 2016. 4. Fares MB, Maco B, Oueslati A, Rockenstein E, Ninkina N, Buchman V, Masliah E, Lashuel HA*.

Induction of de novo α-Synuclein fibrillization in a novel neuronal model for Parkinson’s disease. Proceedings of the National Academy of Sciences USA, 2016, 16;113(7):E912-21.

5. Vieweg S, Ansaloni A, Wang Z, and Lashuel HA*. “An Intein-based Strategy for the Production of

Tag-free Huntingtin Exon 1 Proteins Enables New Insights into the Polyglutamine Dependence of Httex1 Aggregation and Fibril Formation”, J. Biol. Chem, 2016 291(23):12074-86.

6. Fauvet B and Lashuel HA*. “Semisynthesis and enzymatic preparation of post-translationally modified

α-Synuclein”, Methods in Molecular Biology, 2016;1345:3-20. 7. Adamcik J, Sánchez-Ferrer A, Ait-Bouziad N, Reynolds NP, Lashuel HA*, Mezzenga R*.

Microtubule-Binding R3 Fragment from Tau Self-Assembles into Giant Multistranded Amyloid Ribbons. Angew Chem Int Ed Engl. 2016, 11;55(2):618-22.

8. Benmessaoud IR., Mahul-Mellier AL, Horvath E., Maco B., Spina M., Lashuel HA* and Forro L “Health hazards of methylammonium lead iodide based pervoskites:cytoxicity studies”. Toxicology Research, 2016, 5, 407-419. Featured on the Journal Cover

15

9. Oueslati A, Lovisa B, Perrin J, Wagnières G, van den Bergh H, Tardy Y, Lashuel HA*. Photobiomodulation Suppresses Alpha-Synuclein-Induced Toxicity in an AAV-Based Rat Genetic Model of Parkinson's Disease. PLoS One. 2015 Oct 20;10(10):e0140880. doi: 10.1371/journal.pone.0140880. eCollection 2015.

10. Mahul-Mellier A, Vercruysse F, Maco B, Ait-Bouziad N, De Roo M, Muller D and Lashuel HA*

“Fibril growth and seeding capacity play key roles in α-synuclein-mediated apoptotic cell death, Cell Death and Differentiation, 2015, (12):2107-22.

11. Burai R, Ait-Bouziad N, Chiki A, Lashuel HA*. “Elucidating the Role of Site-Specific Nitration of α-

Synuclein in the Pathogenesis of Parkinson's Disease via Protein Semisynthesis and Mutagenesis.” J Am Chem Soc. 2015 Apr 22;137(15):5041-52.

12. Mbefo MK, Fares MB, Paleologou K, Oueslati A, Yin G, Tenreiro S, Pinto M, Outeiro T, Zweckstetter

M, Masliah E, Lashuel HA*. “Parkinson Disease Mutant E46K Enhances α-Synuclein Phosphorylation in Mammalian Cell Lines, in Yeast, and in Vivo.”J Biol Chem. 2015 Apr 10;290(15):9412-27.

13. Ruggeri FS, Adamcik J, Jeong JS, Lashuel HA, Mezzenga R, Dietler G * “Influence of the β-Sheet

Content on the Mechanical Properties of Aggregates during Amyloid Fibrillization”. Angew Chem Int Ed Engl. 2015, 16;54(8):2462-6.

14. Dhungel N, Eleuteri S, Li LB, Kramer NJ, Chartron JW, Spencer B, Kosberg K, Fields JA, Stafa K,

Adame A, Lashuel* H, Frydman J, Shen K, Masliah E, Gitler AD. “Parkinson's Disease Genes VPS35 and EIF4G1 Interact Genetically and Converge on α-Synuclein.” Neuron. 2015 Jan 7;85(1):76-87.

15. Eleuteri S, Di Giovanni S, Rockenstein E, Mante M, Adame A, Trejo M, Wrasidlo W, Wu F, Fraering

PC, Masliah E, Lashuel HA*. “Novel therapeutic strategy for neurodegeneration by blocking Aβ seeding mediated aggregation in models of Alzheimer's disease. ” Neurobiol Dis. 2015, 74:144-57.

16. Bustamante MB, Ansaloni A, Pedersen JF, Cariulo AC, Wang ZM, VeraniM, Puglisi F, Park H,

Lashuel HA and Caricasole A. Detection of huntingtin exon 1 phosphorylation by Phos-Tag SDS-PAGE:Predominant phosphorylation on Threonine 3 and regulation by IKKβ. Biophys. Biochem. Res. Comm. 2015, 463(4):1317-22.

17. Droste P, Frenzel A, Steinwand M, Pelat T, Thullier P, Hust M, Lashuel HA, Dübel S. “Structural

differences of Amyloid-b fibrils revealed by antibodies from phage display” BMC Biotechnol. 2015;15(1):57. doi: 10.1186/s12896-015-0146-8.

18. Khalaf O, Fauvet B, Oueslati A, Dikiy I, Mahul-Mellier AL, Ruggeri FS, Mbefo MK, Vercruysse F,

Dietler G, Lee SJ, Eliezer D, Lashuel HA*. “The H50Q mutation enhances α-synuclein aggregation, secretion, and toxicity.” J Biol Chem. 2014, 289(32):21856-76.

19. Fares MB, Ait-Bouziad N, Dikiy I, Mbefo MK, Jovičić A, Kiely A, Holton JL, Lee SJ, Gitler AD,

Eliezer D, Lashuel HA*. “The novel Parkinson's disease linked mutation G51D attenuates in vitro aggregation and membrane binding of α-synuclein, and enhances its secretion and nuclear localization in cells.” Hum Mol Genet. 2014, 23(17):4491-509.

20. Ansaloni A, Wang ZM, Jeong JS, Ruggeri FS, Dietler G, Lashuel HA*.”One-pot semisynthesis of

Exon1 of the Huntingtin protein: new tools for elucidating the role of post-translational modifications in the pathogenesis of Huntington’s disease” 2014, Angew Chem Int Ed Engl. 10;53(7):1928-33.

16

21. Mahul-Mellier AL, Fauvet B, Gysbers A, Dikiy I, Oueslati A, Georgeon S, Lamontanara AJ, Bisquertt A, Eliezer D, Masliah E, Halliday G, Hantschel O, Lashuel HA*.”c-Abl phosphorylates a-synuclein and regulates its degradation: implications for a-syn clearance and contribution to the pathogenesis of Parkinson’s disease, 2014 Hum Mol Genet. 2014, 23(11):2858-79.

22. Fournier M, Roux A, Garrigue J, Muriel MP, Blanche P, Lashuel HA, Anderson JP, Barbour R, Huang

J, du Montcel ST, Brice A, Corti O. “Parkin depletion delays motor decline does-dependently without overtly affecting neuropathology in a-synuclein transgenic mice. BMC Neurosci. 2013 Nov 5;14:135. doi: 10.1186/1471-2202-14-135.

23. Oueslati A, Schneider BL, Aebischer P, and Lashuel HA* “PLK2 regulates selective autophagic

clearance of a-synuclein and suppresses its toxicity” Proceedings of the National Academy of Sciences USA, 2013, 110(41):E3945-54.

a. Featured in Nature, Neurobiology: Protecting Neurons from Parkinson’s b. Nature, 501, 9, doi:10.1038/501009b c. Featured in Sciencedaily.com: Not Guilty: Parkinson’s Phosphoyrlation d. www.sciencedaily.com/release/2013/08/1308261829

24. Haj-Yahia M, Fauvet B, Herman-Badhinsky Y, Hejjaoui M, Bavikar SN, Vedhanarayanan K,

Ciechanover A*, Lashuel HA* and Brik A*. “Synthetic polyubiquitin alpha-synuclein reveals important insights into the roles of the ubiquitin chain in regulating its pathophysiology” 2013, Proceedings of the National Academy of Sciences USA, 110(44):17726-31

a. Featured as lead story in Chemical & Engineering News: Breaking the Ubiquitin Code http://cen.acs.org/articles/91/i38/Breaking-Ubiquitin-Code.html

25. Fauvet B, Butterfield SM, Fuks J, Brik A, and Lashuel HA*, “One-pot total chemical synthesis of

alpha-synulein”. Chem Commu (Camb), 2013, 49 (81), 9254 - 9256 26. Schmid A, Fauvet B, Moniatte M, and Lashuel HA* “Alpha-synuclein post-translational modifications

as potential biomarkers for Parkinson’s disease and other synucleinopathies, Mol. Cell. Proteomics, 2013, 12(12):3543-58.

27. Santi S, Musi V, Descrovi E, Paeder V, Di Francesco J, Hvozdava L, Van der Wal P, Lashuel HA,

Pastore A, Neier R R, Herzig P. “Real-time amyloid aggregation monitoring with a photonic crystal-based approach, ChemPhysChem, 2013, 14(15):3476-82

28. Schlidnecht S, Gerding HR, Karreman C, Drescher M, Lashuel HA, Outeiro TF, Di Monte DA, and

Leist M. Oxidative and nitrative alpha-synuclein modifications and proteostatic stress: Implications for disease mechanisms and interventions in synucleinopathies, J Neurochem, 2013, 124(4), 491-511

29. Lashuel HA, Overk C, Ouelati A, and Masliah E “α-synuclein oliogmerizatoin in health and disease”,

Nature Rev. Neuroscience, 2013 Jan;14(1):38-48. 30. Wang Z and Lashuel HA* “Discovery of a novel aggregation domain in the Huntingtin Protein:

Implications for the mechanisms of Htt aggregation and toxicity”, 2013, Angewandte Chem. Int. Ed, 2013 2013 Jan 7;52(2):562-7.

a. Featured in the cover page as a VIP paper b. Featured in Chemical and Engineering News c. Featured in CHIMIA

17

31. Jeong JS, Ansaloni A, Mezzenga R, Lashuel HA*, and Dietler G* “Novel mechanistic insight into the molecular basis of amyloid polymorphism and secondary nucleation during amyloid formation” J. Mol. Biol. 2013, 425(10):1765-81.

32. Shabek N, Herman-Bachinsky Y, Buchsbaum S, Lewinson O, Haj-Yahya M, Hejjaoui M, Lashuel HA,

Sommer T, Brik A, Ceichanover A. “The size of the proteasomal substrate determines whether its degradation will be mediated by Mono- or Polyubiquitination. Mol. Cell. 2012, 12;48(1):87-97

33. Hejjaoui M, Butterfield S, Fauvet B, Vercryusse F, Cun J, Dikiy I, Prudent M, Olschewski D, Zhang Y,

Eliezer D., Lashuel HA* “Chemical Biology of α-synuclein: Elucidating the role of C-terminal post-translational modifications using protein semisynthetic strategies: Phosphorylation at Tyrosine 125”, J. Amer. Chem. Soc, 2012. 21;134(11):5196-210.

34. Oueslati A, Paleologou KE, Schneider BL, Aebischer P., Lashuel HA* “Mimicking phosphorylation at

Serin87 inhibits the aggregation of human alpha-synuclein and protects against its toxicity in a rat model of Parkinson’s disease, J. Neuroscience, 2012, 1;32(5):1536-44.

35. Fauvet B., Mebfo MK, Fares BM, Desobry C, Michael S, Ardah MT, Tsika E, Coune P, Eliezer D,

Moore DJ, Schneider B, Aebischer P., El-agnaf OM, Masliah E, and Lashuel HA* “Alpha-synuclein in the central nervous system, in mammalian cells, and produced by E. coli exists predominantly as a disorderd monomer”, 2012, J. Biol. Chem, 287, 15345-15364

36. Butterfield S, Hejjaoui M, Fauvet B, and Lashuel HA* “Chemical approaches to elucidate the

mechanisms of amyloid formation and toxicity”, J. Mol. Biol, 2012, 421, 204-236 37. Fauvet B, Fares BM, Samuel F, Kikiy I, Tandon A, Eliezer D, Lashuel HA* ” Characterization of

semisynthetic and natural N-terminal acetylated α-synuclein in vitro and in intact cells: Iimplications for a-synuclein aggregation and cellular properties” J. Biol. Chem. 2012, 17;287(34):28243-62.

38. Kroth H, Ansaloni A, Varisco Y, Jan A, Nampally S, Giriens V, Lohman S, Lopez-Deber M, Adolfsson

O, Pihlgren M, Paganetti P, Froestl W, Nagel-Steger L, Willbold D, Schrader T, Pfeifer A, Lashuel HA., Muhs A. “ Discovery and structure activity relationship of small molecule inhibitors of amyloid toxicity. 2012, J. Biol. Chem. 5;287(41):34786-800.

39. El-turk F., Fauvet B., Cho MK., Ouertatani-Sakouhi H., Neri M., Cascella M, Rothlisberger U.,

Zweckstetter M., and Lashuel HA* “Characterization of Molecular Determinants of the Conformational Stability of Macrophage Migration Inhibitory Factor: Leucine 46 Hydrophobic Pocket”, PLoS One, 2012, 7(9):e45024.

40. Jan A and Lashuel HA*. Biophysical Approaches for Establishing the Links between Aβ aggregation

and toxicity. Methods Mol. Biol. 2012, 849, 227-43 41. Yang B, Sun X, Lashuel HA, Zhang Y “Reactive Oxidative Species is involved in Enhanced Amyloid

Toxicity in APP/PS1 Mouse Neurons”, 2012 Neuroscience Letter. 28(3):233-9. (Impact Factor = 2.1) 42. Adamcik J, Lara C, Usov I, Sun Jeong J, Ruggeri S. F., Kietler G, Lashuel HA, Hamley I. W.,

Mezzenga R “Measurement of intrinsic properties of amyloid fibrils by peak force QNM method”, Nanoscale, 2012, 4, 4426-4429.

18

43. Choi HS, Liew H, Jang A, Kim YM, Lashuel HA, Suh YH. “Phosphorylation of a-synuclein is crucial in compensating for proteasomal dysfunction” Biochem. Biophys. Res Commun. 2012, 424(3):597-603.

44. Yu L, Prudent M, Fauvet B, Lashuel HA* and Girault H “Phosphorylation of a-synuclein at Y125 and

S129 alters its metal binding properties: Implications for understanding the role of a-synuclein in the pathogenesis of Parkinson’s disease and related disorders”. ACS Chem. Neurosci., 2012, 2, 667–675.

45. Jan A, Adolfsson O, Allaman I, Buccarello AL, Magistretti PJ, Pfeifer A, Muhs A, Lashuel HA*,

“Aβ42 neurotoxicity is mediated by ongoing nucleated polymerization process rather than by discrete Aβ42 species”. J. Biol. Chem, 2011, 286(10):8585-96.

46. Siman P, Blatt O, Moyal T, Danieli T, Lebendiker M, Lashuel HA, Friedler A, Brik A. “Chemical synthesis and expression of the HIV-1 Rev Protein” ChemBiochem 2011, 2;12(7):1097-104.

47. Follmer C., Braga CA., Khattar E., Palhano F., Freitas MS., Romao L., Lashuel HA., Silva JL, Foguel D. “ The anti-Parkinsonian drug Selegiline (R(-)-Deprenyl) delays the nucleation phase of α-synuclein aggregation and this effect its reversed by dopamine: implications for Parkinson’s disease. J. Mol. Biol, 2011, 7;405(1):254-73.

48. Hejjaoui H, Haj-Yahya M, Kumar KS, Brik A* and Lashuel HA* “Towards elucidating the role of ubiquitination in the pathogenesis of Parkinson’s disease using semisynthetic ubquitinated α-synuclein”. Angew Chem Int Ed, 2011, 10;50(2):405-9.

49. Conboy L, Varea E, Ouertatani-Sakouhi H, Calandra T, Lashuel HA, Sandi C. “Essential role of macrophage migration inhibitory factor (MIF) on hippocampal neurogenesis, antidepressant effects and behavior”. 2011, Mol. Psychiatry, 16(5):533-47.

50. Paleologou KE., Oueslati Abid, Kim H-Y, Lamberto GR., Rospigliosi CC., Schmid A., Chiappe D., Moniatte M., Eliezer D., Zweckstetter M., Masliah E. Lashuel HA*.” Phosphorylation at S87 is enhanced in synucleinopathies, inhibits alpha-synuclein oligomerization, and influences synuclein-membrane interactions” J. Neuroscience, 2010, 3;30(9):3184-98.

51. Mbefo MK, Paleologou KE, Boucharaba A, Oueslati A, Olschewski D, Schell H, Fournier M,

Zweckstetter M., Kahle PJ, Masliah E Hirling H, and Lashuel HA*. “Phosphorylation of synucleins (α, β and γ) by members of the Polo Like family of Kinases, PLKs 1-4”, 2010, J. Biol. Chem, 285(4):2807-22.

52. Oueslati A¥, Fournier M¥, and Lashuel HA*. “Role of post-translational modifications in modulating α-

synuclein structure, aggregation and toxicity: implications for Parkinson’s disease pathogenesis and therapies”. Prog Brain Res. 2010;183C:115-145.

53. Allaman I., Gavillet M., Belanger M., Laroche T., Virtel D, Lashuel HA, Magistretti PJ. “Beta-amyloid aggregates cause alteration of astrocytic metabolic phenotype: impact on neuronal viability”, J. Neuroscience, 2010, 3;30(9):3326-38.

54. Di Giovanni S, Eleuteri SC, Paeologou KE, Zweckstetter M, Carrupt PA, Lashuel HA* “Entacapone

and Tolcapone, two catechol-O-methyltransferase inhibitors, block fibril formation of α-syn and Aβ and protect against amyloid induced toxicity”. J. Biol. Chem, 2010, 285(20):14941-54.

19

55. Jan A, Hartley DM and Lashuel HA*. “Preparation and characterization of toxic Aβ intermediates for structural and functional studies in Alzheimer’s disease research”. Nature Protocols, 2010;5(6):1186-209.

56. Butterfied SM and Lashuel HA*. “Amyloidogenic protein-membrane interactions: mechanistic insights from model systems”. Angewandte Chem. Int. Ed, 2010, 49, 5628-5654.

57. Ouertatani-Sakouhi H, El-Turk F, Fauvet F, Cho MK, Roger T, Dewor M, Bernhagen J, Calandra T, Zweckstetter M. Lashuel HA*. “Identification and characterization of novel classes macrophage migration inhibitory factor (MIF) inhibitors with distinct mechanisms of action”. J. Biol. Chem. 2010. 34, 26581-26598.

58. Elturk, Fauvet B, Ouertatani-Sakouhi, Lugari A, Betzi S, Roche P, Morelli X and Lashuel HA*. “ An integrative in silico methodologies for the identification of small molecule inhibitors of Macrophage Migration Inhibitory factor”. Bioorg. Med. Chem., 2010, 18(14):5425-40.

59. Ouertatani-Sakouhi H., Liu M., El-turk F., Cuny GD., Glicksman MA., and Lashuel HA* “ Kinetic based high-throughput screening assay to discover novel classes of Macrophage Migration Inhibiotry Factor inhibitors”. J. Biomolecular Screening, 2010, 15(4):347-58.

60. Hinault MP, Cuendet AF, Mensi M, Dietler G, Lashuel HA, Goloubinoff P. “Stable α-synuclein oligomers inhibit Hsp70 chaperone activity by interacting with J-domain co-chaperones”. 2010, J. Biol. Chem. 285(49):38173-82.

61. Khandelwal P., Dumanis SB., Maguire-Zeiss K., Lashuel HA., Rebeck W., and E-H Moussa C. “Parkinson-related parkin effects on cellular mechanisms in gene transfer model of neurodegeneration”, Molecular Neurodegeneration, 2010, 5:47doi:10.1186/1750-1326-5-47.

62. Grimminger V., and Lashuel HA* “Structure and function of the molecular chaperone Hsp104 from yeatst”, 2010, Bioploymers, 2010, 93(3):252-76.

63. Schmid A.,Chiappe D., Pignet V., Chiappe D., Grimminger V., Hang, I., Moniatt M., Lashuel HA*.

“Dissecting the mechanisms of tissue transglutaminase induced cross-linking of α-synuclein: Implications for the pathogensis of Parkinson’s disease”. 2009, J. Biol. Chem. 284(19):13128-42.

64. Rospigliosi CC., McClendon S, Schimd AW., Ramlall TF., Barre P., Lashuel HA., Eliezer D. “The

E46K Parkinson’s-linked mutation enhances C- to N-terminal contacts in α-synuclein”, J. Mol. Biol, 2009, 388(5):1022-32.

65. Camus MS, Mimna R, Schmid A, Chandravarkar A, Tuchscherer G, Lashuel HA, Mutter M. “Switch-

peptides as folding precursors in self-assembling peptides and amyloid fibrillogenesis” Adv Exp Med Biol. 2009;611:281-2.

66. Fournier M, Garrigue J, Vitte J, Langui D, Dullin JP, Saurini F, Hanoun N, Perez-Diaz F, Cornilleau F,

Joubert C, Ardila-Osorio H, Traver S, Duchateau R, Goujet-Zalc C, Paleologou K, Lashuel HA, Haass C, Duyckaerts C, Cohen-Salmon C, Kahle P, Hamon M, Brice A, Corti O. Parkin deficiency modulates alpha-synuclein pathology and disease progression in a mouse model of synucleinopathy, 2009, PLoS ONE, Aug 14;4(8):e6629.

20

67. Ouertatani-Sakouhi H., El-turk F., Lashuel HA*. “Novel classes of small molecule inhibitors of the catalytic and biological activity of macrophage migration inhibitory factor (MIF)”, Biochemistry, 2009, 48, 9858-9870.

68. Kumar KA, Haj-Yahya M, Olschewski D, Lashuel HA, Brik A. "Highly efficient and chemoselective

peptide ubiquitylation". Angew Chem Int Ed, 2009, 48(43):8090-4.

69. Cho MK., Kim HY., Kumar A., Maier E., Siebenhaar C., Becker S., Fernandez CO., Lashuel HA., Benz R., Lang A., and Zweckstetter M. “Micro-mole scale pore forming oligomers by cold-induced dissociation of amyloid”. J. Amer Chem Soc, 2009, 131, 17482 –17489.

70. Lashuel HA*and Pappu RA. “Amyloid go genomics: “Insights regarding the sequence determinants of prion formation from genome-wide studies” ChemBiochem, 2009, 10(12):1951-1954.

71. Paleologou KE., Schmid A., Rospigliosi CC, Kim H-Y, Lamberto GR., Fredenburg RA., Lansbury PT, Jr., , Fernandez CO., Eliezer D., Zweckstetter M., Lashuel HA*. “Phosphorylation at Ser-129 but not the phosphomimics S129E/D inhibits the fibrillation of alpha-synuclein”. J. Biol. Chem, 2008, 283:16895-905.

72. Camus M-S., Santos S-D, Chandravarkar A., Mandal B., Schmid A., Tuchscherer G., , Mutter M.

Lashuel HA* Switch-Peptides: Switch Peptides: Design and characterization of controllable super amyloid forming host-guest peptides as tools for identifying anti-amyloid agents. ChemBioChem, 2008, 9, 2104-2112.

73. El-turk F., Michele C., Ouertatani-Sakouhi H., Zweckstetter, M., Leng L, Bucala R., Röthlisberger U.,

Lashuel HA*. “The role of the carboxy terminal residues 104-114 in modulating the conformational flexibility and catalytic activity of Macrophage migration inhibitory factor (MIF)”. Biochemistry 2008, 47(40):10740-10756.

74. Herrera F., Chesi A, Paleologou KE. Schmid A., Munoz A, Vendruscol M, Gustincich S, Lashuel HA.,

and Carloni P. “Inhibition of alpha-synuclein fibrillation by dopamine is mediated by the C-term and Glu83 in the NAC region”. PLOS One, 2008, 3394-3407.

75. Jan A., Goekce Ol, Luthi-Carter R., and Lashuel HA*. The ratio of monomeric/ aggregated forms of

Aβ (40&42) is an important determinant of Aβ aggregation and fibrillogenesis in Alzheimer’s diseases. J. Biol. Chem, 2008, 283(42):28176-89.

76. Lo Bianco C., Shorter J. Régulier E., Lashuel HA., Iwatsubo T., Lindquist S., Aebischer P. “Hsp104

Antagonizes α-Synuclein Aggregation and Reduces Dopaminergic Degeneration in a Rat Model of Parkinson’s Disease. J. Clinc. Inv, 2008, 118, 3087-3098.

77. Nepomniaschiy N., Grimminger V., Cohen A., DiGiovanni S., Lashuel HA*, and Brik A*. “Design

and synthesis of a novel switch for triggering acyl migration and peptide self-assembly” Org. Letters , 2008, 10(22):5243-6.

78. Arimon M., Grimminger V., Sanz F., Lashuel HA*. ”Hsp104 targets multiple intermediates on the

amyloid pathway and suppresses the seeding capacity of fibrils and protofibrils of Aβ”. J. Mol. Biol, 2008, 384(5):1157-1173.

21

79. Mimna R., Camus M-S., Schmid A., Tuchscherer G., Lashuel HA*, Mutter M*. “Switch Peptides: Disruption of amyloid fibrils through controlled induction of β-sheet to α-helix transformation” Angewandte Chem. Int. Ed., 2007, 46, 2681-2684.

80. Follmer, C, Romao L, Einsiedler C, Porto T, Alves-Lara F, Lashuel HA, Lansbury PT, Neto VM, Silva

JL, and Foguel D. “ Dopamine affects the stability, hydration and packing of protofibrils and fibrils of wild-type and variants of α-synuclein”. Biochemistry, 2007, 46, 472-482.

81. Tuchscherer G., Chandravarkar A., Camus MS, Berard J., Schmid A., Bhubaneswar M, Murat K,

Mimna R, Lashuel HA., Mutter M. “Switch peptides as folding precursors in self-assembling peptides and amyloid fibrillogenesis”. Biopolymers, 2007, 88, 2, 239-252.

82. Fredenburg RA., Rospigliosi C., Meray R., Kessler JC., Lashuel HA, Eliezer D., and Lansbury PT Jr.

“The Impact of the E46K Mutation on the Properties of α-Synuclein in its Monomeric and Oligomeric States”. Biochemistry, 2007, 46, 7107-7118.

83. Chafekar SM., Malda H., Merkx M., Meijer BW., Lashuel HA., Baas F., Scheper W*. “Coupling of

KLVFF to dendrimers strongly potentiates inhibition of β-amyloid aggregation”. ChemBiochem, 2007, 8, 1857-1864.

84. Lansbury PT* and Lashuel HA*. “A century-old debate on protein aggregation and neurodegeneration

enters the clinic. Nature, 2006, 443, 774-779. 85. Lashuel HA* and Harald Hirling. “Rescuing defective vesicular trafficking protects against α-

synuclein toxicity in cellular and animal models of Parkinson’s disease. ACS Chemical Biology, 2006, 1(7), 1, 420–424.

86. Lashuel HA* and Lansbury PT*. "Are amyloid diseases caused by protein aggregates that mimic

bacterial pore-forming toxins?" Quarterly Review of Biophysics. 2006, 39 (2), 1-35. 87. Saucede L., Santos SD., Chandravarkar A., Mandal B., Murat K., Camus, M-S., Berard, J., Grouzmann,

E., Adrian M., Dubochet J., Lopez J, Lashuel HA., Tuchscherer GT., Mutter M. “ “Switch Peptides: From Conformational Studies to Alzheimer’s Disease”. CHIMIA, 2006, 60, 199-202.

88. Wang, L., Lashuel, HA, and Colón, W. From Hexamer to Amyloid: The Mechanism of Serum

Amyloid A Fibril Formation. Amyloid: The Journal of Protein Folding Disorders, 2005, 12, 139-148. 89. Basha R, Murali M, Siddiqi HK, Ghosal K, Siddiqi OK, Lashuel HA, Zawia NH. Exposure to lead (Pb)

promotes b-amyloid aggregation but does not affect the proteolytic processing of the Amyloid Precursor Protein (APP), FASEB J, 2005, 19, 2083-2093.

90. Morikawa M, Fryer JD, Sullivan PM, Christopher EA, Wahrle SE, DeMattos, O'Dell MA, Fagan AM,

Lashuel HA, Walz T, Asai K, and Holtzman D. “Production and characterization of astrocyte-derived human apolipoprotein E isoforms from immortalized astrocytes and their interactions with amyloid-ß “Neurobiology of Disease, 2005, 19 (1-20), 66-76.

91. Lashuel HA*. "Membrane Permeabilization: A Common Mechanism in Protein Misfolding Diseases:

If it looks like a pore and acts like a pore, is it a pathogenic pore?". Sci Aging Knowledge Environ. 2005 (38), pe28 (2005).

22

92. Cox DL, Lashuel HA, Lee KY, and Singh R.R.P. The materials science of protein aggregation. Material Research Society Bulletin. 2005, 30, 6, 452-457.

93. Lashuel HA*, Aljabari B, Sigurdsson EM, Metz CN, Leng L, Callaway DJ, and Bucala R. "Amyloid

Fibril Formation by Macrophage Migration Inhibitory Factor (MIF)", Biochem. Biophys. Res. Commun, 2005, 6; 338, 973-980.

94. Nakagawa T, Futai K, Lashuel HA, Lo I, Okamoto K, Hayashi Y, Walz T, and Sheng M. EM

Structure, Protein Dynamics and Synaptic Function of SAP97, and AMPA Receptor Scaffold Protein. Neuron, 2004, 28;44(3):453-467.

95. Rochet JC, Outeiro TF, Conway KA, Ding TT, Volles MJ, Lashuel HA, Bieganski RM, Lindquist SL,

and Lansbury PT, Jr. Interactions Among α-synuclein, Dopamine and Biomembranes. J. Mol. Neurosci. 2004, 23, 23-33.

96. Lashuel HA, Hartley D, Petre B, Wall, Simon M, Walz T, Lansbury PT . Mixtures of wild-type and a

pathogenic (E22G) form of A40 in vitro accumulate protofibrils, including amyloid pores. J. Mol. Biol. 2003, 332, 795-808.

97. Ferrao-Gonzales AD, Palmieri L, Valory M, Silva JL, Lashuel HA, Kelly JW, Foguel D. Hydration

and Packing are Crucial to Amyloidogenesis as Revealed by Pressure Studies on Transthyretin Variants that Either Protect or Worsen Amyloid Disease. J. Mol. Biol. 2003, 328, 4, 963-974.

98. Liu Y, Lashuel HA, Choi S, Xing X, Case A, Ni J, Yeh L, Cuny, GD, Stein RL, and Lansbury PT, Jr.

A Class of Small Molecule UCH-L1 Inhibitors: Chemical Genetic Tools to Probe the Pathogenesis of Parkinson’s Disease and Cancer. 2003, Chemistry & Biology. 2003, 10, 837-846.

99. Kheterpal I*, Lashuel HA*, Hartley DM, Walz T, Lansbury PT Jr., Wetzel R. Aβ protofibrils possess a

stable core structure resistant to hydrogen exchange. Biochemistry. 2003, 42, 14092-14098. 100. Foguel D, Suarez MC, Ferrão-Gonzales AD, Porto TR, Palmieri L, Einsiedler C, Lashuel HA,

Lansbury PT, Kelly JW, and Silva JL. Dissociation of Amyloid Fibrils of -Synuclein and Transthyretin by Pressure Reveals their Reversible Nature and the Formation of Water-Excluded Cavities. Proceeding of the National Academy of Science, U.S.A. 2003, 100, 9831-9836.

101. Bitan G, Tarus B, Lashuel HA, Vollers SS, Condron MM, Straub E, Teplow DB. A Molecular Switch in Amyloid Assembly: Met35 and Amyloid -protein Oligomerization. Journal of the American Chemical Society. 2003, 125, 15359-15365.

102. Lashuel HA, Hartley D, Petre B, Walz T, Lansbury PT. Neurodegenerative Disease, Amyloid Pores

from Pathogenic Mutations. Nature. 2002, 418, 291-291. 103. Liu Y, Fallon L, Lashuel HA, Liu Z, Lansbury PT. The UCH-L1 Gene Encodes Two Opposing

Enzymatic Activities that Affect alpha-Synuclein Degradation and Parkinson's Disease Susceptibility. Cell. 2002 ,111, 209-218.

104. Lashuel HA*, Hartley D, Balakhaneh D, Teichberg S, Callaway DE*. New Class of Inhibitors of

Amyloid-β (Aβ) Fibril Formation: Implications for the Mechanism of Pathogenesis in Alzheimer’s disease. J. Biol. Chem. 2002, 277: 42881-42890.

23

105. Lashuel HA, Petre B, Wall, Simon M, Nowak RJ, Walz T, Lansbury PT. -Synuclein, Especially the Parkinson’s Disease-Associated Mutants, Form Pore-like Annular and Tubular Protofibrils. J. Mol. Biol. 2002, 322, 5, 1089-1102.

106. Wang, L, Lashuel HA, Walz, T. and Colon F. Serum Amyloid A Forms a Hexamer with a Central

Channel. Proceeding of the National Academy of Science, 2002, 99, 15947-15952. (Impact Factor = 9.7)

107. Oza VB, Smith C, Raman P, Koepf EK,, Lashuel HA, Petrassi M, Chiang K, Powers ET, Sachettinni J,

and Jeffery W. Kelly. J. Synthesis, structure, and activity of diclofenac analogues as transthyretin amyloid fibril formation inhibitors. Med. Chem., 2002, 45, 321-332. (Impact Factor = 5.2)

108. Lashuel HA, LaBrenz SR, Woo L, Kelly JW. A Peptidomimetic that forms Cables, Monolayers (or

Bilayers) or Fibrils Depending on Solution Conditions: Implications for Material Science and Neurodegenerative Diseases. Journal of the American Chemical Society, 2000, 122, 22, 5262-5277.

109. Gingolani G, Lashuel HA, Gerace L, Müller CW. Nuclear import factors importin and importin

undergo mutually induced conformational changes upon association. FEBS Letters, 2000, 484, 291-298.

110. Liu K, Cho HW, Lashuel HA, Kelly JW, Wemmer DE. A Glimpse of a Possible Amyloidogenic

Intermediate of Transthyretin. Nature Structural Biology, 2000, 7, 754-757. 111. Lashuel HA, Wurth C, Woo L, Kelly JW. The Most Pathogenic Transthyretin FAP-Associated Variant,

L55P, Forms Amyloid Fibrils Under Physiological and Acidic Conditions. Biochemistry, 1999, 38, 13560 - 13573.

112. Atkins AR, Lashuel HA, Kelly JW, Edelman GW, Wright PE, Cunningham BA, Dyson J. Association between the first two Immunoglobulin-like domains of the Neural Cell Adhesion Molecule N-CAM. FEBS Letters, 1999, 451, 162-168.

113. Chitnumsub P, Fiori WR, Lashuel HA, Diaz H. Kelly JW. The Nucleation of Monomeric Parallel -

Sheet-like Structures in Aqueous Solutions. Bioorganic & Medicinal Chemistry. 1999, 7, 1, 39-59.

114. Lashuel HA, Lai Z, Kelly JW. Characterization of the Transthyretin Acid Denaturation Pathway by Analytical Ultracentrifugation: Implications for wild type, V30M and L55P Amyloid Fibril Formation. Biochemistry. 1998, 37, 51, 17851-17864. (Impact Factor = 3.4)

115. Patricelli MP, Lashuel HA, Kelly JW, Cravatt BF. Comparative Characterization of Wild Type and

Transmembrane Domain-Deleted Fatty Acid Amide Hydrolase: Identification of the Transmembrane Domain as a Site for Oligomerization. Biochemistry 1998 37, 15177-1518.

116. Xie Y, Lashuel HA, Miroy GJ, and Kelly JW. Efficient Refolding and Characterization of Recombinant Human Plasma Retinal-Binding Protein from Inclusion Bodies in E.coli. Protein Expression and Purification. 1998, 14, (1), 31-37.

117. Hengst L, Lashuel HA, Reed SI. One Molecule of p21Kip1Is Sufficient to Inhibit One CdK/Cyclin

Complex. Genes & Development. 1998, 12, 3882-3888. 118. Peterson SA, Klabunde T, Lashuel HA, Purkey H, Sacchettini JC, Kelly JW. Inhibiting Transthyretin

Conformational Changes that Lead to Amyloid Fibril Formation. Proceedings of the National Academy of Science. U.S.A. 1998, 95, 12956-12960.

24

119. Xiangang Z, Zhu H, Lashuel HA, Hu J. Probing the Oligomerization Properties of GCN4 Leucine

Zipper e & g Position Mutants. Protein Science. 1997, 6, 2218-2226. 120. Lai Z, McCulloch J, Lashuel HA, Kelly JW. GdnHCL Induced Denaturation and Refolding of

Transthyretin Exhibits a Marked Hysteresis: Equilibria with High Kinetic Barriers. Biochemistry. 1997, 36, 33, 10230-10239.

121. Miroy GJ, Zhihong L, Lashuel HA, Peterson SA, Strang C, Kelly JW. Inhibiting Amyloid Fibril

Formation via Protein Stabilization. Proceedings of the National Academy of Science. U.S.A. 1996, 93, 15051-1506.

5. REFERRED BOOK CHAPTERS

1. Jan A and Lashuel HA*. Biophysical Approaches for Establishing the Links between Aβ aggregation and toxicity. Methods Mol. Biol. 2012, 2012;849:227-43.

2. Lashuel HA*. In Vitro Preparation of Prefibrillar Intermediates of Amyloid- (A) and -Synuclein. Methods Mol. Biol. 2005, 299, 19-33.

3. Lashuel HA* and Joseph Wall. Molecular Electron Microscopy Approaches to Elucidating the

Mechanism of Amyloid Fibril Formation. Methods Mol Biol. 2005, 299, 81-101. 4. Colon W, Zhihong L, Lashuel HA, McCulloch J, McCutchen S, Miroy GJ, Peterson SA, Kelly JW.

Transthyretin Conformational Changes Facilitate Misassembly into Amyloid: A New Therapeutic Strategy Based on Preventing the Amyloidogenic Conformational Changes. Advances in Protein Chemistry, “Protein Misassembly” 1997, 161-179. Edited by Ronald Wetzel, Academic Press.

6. MEETING REPORTS

1. Kimberly TW, Kovacs DM, Walsh D, Lashuel HA, Lemere CA. The 8th International Conference on

Alzheimer’s Disease and Related Disorders. Amyloid, 2003, 10, 51-61.

7. ARTICLES ON SCIENCE AND EDUCATION IN THE MIDDLE EAST

1. Call for Reform”Associate Professor of life sciences at Brain Mind Institute of Ecole Polytechnique Federale de Lausanne in Switzerland, Hilal Ahmed Lashuel speaks about GCC educational reforms”., Interview by Ranvir Nayar, Paris, TRENDS magazine, 2012, Dubai.

2. Lashuel HA and Al-Delaimy WK, “Arab world needs its science diaspora”, Nature, 2011, 472, 418

3. Al-Delaimy WK and Lashuel HA. “Gulf states should work together on research:A regional strategy and a focus on capacity building would strengthen Gulf investments in Science &Technology. Science and Development Network, June 11th, 2008 (hyperlink to the page on scidev website http://www.scidev.net/en/opinions/gulf-states-should-work-together-on-research.html)

25

4. Lashuel HA and Zawia N. "Islam: governments need to reform education and build a scientific culture". Nature, 2006, 444, 545.

8. PATENTS

1. Lashuel HA, Burai R, Mathur V and Wyss-Coray A. 2016, “Ganciclovir Derivatives for Modulating Innate and Adaptive Immunity and for Use in Immunotherapy” Joint filing with Stanford University on 09/08/2015

2. Lashuel HA and Hajer Ouertatani-Sakouhi. 2009, “Method and Substances for inhibition of tautomerase activity of macrophage migration inhibitory factor (MIF). WO 2009/031545.

3. Lashuel HA, Callaway DE. Use of apomorphine derivative or its analogs for inhibition or reduction of amyloid beta fibril formation and for delaying onset of Alzheimer’s disease. 2003, WO2003053356-A; WO2003053356-A2; AU2002357911-A1; US2003187011-A1.

4. Miroy GJ, Kelly JW, Lai Z, Lashuel HA, Petterson SA. Treatment of amyloid disease using amyloidogenic protein-stabilizing compounds - used to treat a variety of amyloid diseases including Alzheimer's disease, mad cows disease etc. 1998 WO9827972-A; WO9827972-A2; AU9857277-A

26

INVITED LECTURES ONLY

2016-2017 1. The Annual Alpha-Synuclein Summit organized by the Michael J Fox Foundation, New York, USA,

February 16th, 2017. 2. Oxford University, Oxford Parkinson’s Disease Center Seminar Series, Oxford, UK, May 16th, 2017 3. Cambridge University , Department of Chemistry, Cambridge, UK May, 2017 4. Inauguraal symposium of the Institute of Biostructural Imaging of Neurodegeneration, Goettingen,

Germany, May 30-31, 2017. 5. 2017 FASEB Science Research Conference on Protein Aggregation in Health & Disease, Steamboat

Springs, Colorado, USA, June 11-16th, 2017 6. The Latsis/EPFL BMI Symposium ‘Degeneration of Neuronal Circuits’, EPFL, September 4-5, 2017 7. 20 years of Alpha-Synuclein in Parkinson’s disease and related synucleinopathies; from the bedside to

the bench and back to the patient. Athens, Vravrona, September 7-10, 2017 5. Gordon Research Conference, Chemistry and Biology of Peptides GRC, February 21-26, 2016,

Ventura, CA, USA 6. CHDI Therapeutic Conference, Feb 22-23, 2016, Palms Spring, CA, USA 7. Qatar Foundation Annual Research Conference; Biomedical and Health Research in Qatar; Translating

Challenges into Competitive Advantages and Economic Opportunities. Session organizer and moderator of the panel discussion

8. UCB Super Network Conference, March 13-15th, 2016, London, UK. 9. Keynote Lecture: Wilder-Penfield Memorial Lecture “Precision Medicine applied to 10. Neurodegenerative Diseases” at Middle East Annual Assembly meeting, “Precision Medicine: A new

Era towards Personalized Healthcare” American University of Beirut, May 13-15th, Beirut Lebanon 11. Federation of European Neuroscience Societies Forum of Neuroscience; alpha-synuclein prion like

forms as target for therapy in Parkinson’s disease and other synucleinopathies, July 5th, 2016. 12. First Translational Neuroscience Summer School organized by Technical University of Munich, The

International Parkinson and Movement Disorder Society (MDS), and the German Academic Exchange Service (DAAD) in El Gouna, Egypt, September 6-8th, 2016.

13. Technical University Munich, Munich Cluster for Systems Neurology Seminar series, September 20th, 2016

14. Diabetes Leadership Fourm: Qatar National Diabetes Research Strategy, September 26th, 2016 15. 5th Annual International Chemical Biology Society Conference (ICBS 2016 Conference), Wisconsin

Madison, USA, October 24-26th, 2016 16. Diabetes Leadership Forum, Qatar National Research Strategy, Doha, Qatar, September 26-27th, 2016. 2015 17 International Parkinson’s and Movement Disorders Society- European Section. Alpha-Synulcein: the

Gateway to Parkinsonism, Innsbruck, Austria, Feb 11-13, 2015 18 American Chemical Society National Meeting taking place during the week of 22-26, March 2015 in

Denver, CO. 19 Molecular Mechanisms of Neurodegeneration in hereditary disease (VI meeting), May 28-30th, 2015 in

Milano Italy 20 FASEB Molecular Mechanisms and Physiological Consequences of Protein Aggregation, Jun 21- 26,

2015, Palm Beach FL. 21 First Sino-Swiss Symposium in Translational Medicine, June 29th – July 1st, Tianjin International

Academy of Biomedicine, Tianjin- China. 22 Lead Organizer and Lecturer: Advanced Neuroscience School on Protein Misfolding and

Accumulation: Cellular Mechanisms, Imaging and Drug Development, August 22-29th, 2015.

27

23 Keynote Speaker: Life Science PhD days orgSanized by University of Luxembourg, September 21st -22nd , 2015 in Belval/ Luxembourg.

24 Grand Challenges in Parkinson’s Disease Annual Meeting, September 30th – October 1st, 2015. Van Andel Research Institute, Grand Rapids-Michigan, USA

25 ICBS-ECBS International Chemical Biology Society Meeting, October 7-9th, 2015, in Berlin Germany 26 University of Pennsylvania Department of Biochemistry and Molecular Biophysics (BMB), Nov 17th,

2015, Pennsylvania, USA

2014 27. Swiss Society of Neuroscience Annual Meeting, Bern, Switzerland, January 25th, 2013 28. Join t 2014 Keystone Symposia on Parkinson’s Disease: Genetics, Mechanisms and

Therapeutics/Alzheimer’s Disease – From Fundamental Insights to Light at the End of the Translational Tunnel. These meetings will be held March 2-7, 2014

29. International Symposium “New frontier of molecular neuropathology”, Riken, Tokyo, March 16-17, 2014

30. Barcelona Biomed Conference on Amyloid and Alzheimer’s disease, Barcelona July 10-11th, 2014 31. EMBL Chemical Biology Conference, Heidelberg, Germany, August 20-23rd, 2014 32. Science and Technology Society Forum, Kyoto, Japan, October 6-8th, 2014 33. Brain Conference 2014, the joint conference of Korean Society for Brain and Neural Science, Korean

Society for Neurodegenerative Diseases, and Asian Congress of Neuropathology. The conference will be held in Seoul, Korea on Nov 6th-8th, 2014. " Targeting conformations in diagnosis and therapy for neurodegenerative diseases."

34. Harvard Arab Alumni Association. Harvard University "Re-emergence of Science in the Middle East", Boston, USA, November 6-9, 2014.

35. IBRO-MENA Neuroscience School in Neurogenetics, December 10-16th, 2014, QBRI, Doha-Qatar 36. IBRO-MENA Neuroscience Research Symposium, QBRI, Doha-Qatar

2013 37. Department of Neurology and Neurological Sciences Annual Retreat, Stanford University Jan, 2013. 38. Genentech, San Francisco, January 22nd, 2013. 39. International Conference on "Alpha-synuclein in Parkinson's disease and related neurodegenerative

diseases: From Mechanisms to Therapeutic Strategies", March 1-3rd, 2013. 40. AD/PD Conference, Florence Italy, March 6-10th, 2013 41. Young Global Leaders Future Development Summit, March 17-19th, 2013 42. American Physical Society Annual Meeting, "Physics of Proteins II: Protein Association,

Interaction,and Aggregation." Baltimore, USA, March 18-22nd, 2013 43. 5th Chemical protein synthesis (CPS) Meeting, Vienna, Austria, April 3-6th, 2013 44. CHDI's 8th Annual HD Therapeutics Conference - Venice, Italy, April 8-11, 2013 45. Neuroscience School of Advanced Studies, Protein Aggregation Spectrum Disorders, June 15-23, 2013 46. European Biophysical Society, Lisbon, Portugal, July 13-17th, 2013. 47. 2013 FASEB Summer Research Conference on Molecular Mechanisms and Physiological

Consequences of Protein Aggregation. 48. MEFOPA & Neurasync Final Meeting September 19-21 2013, Rome 49. Stepping Stone Symposium, China, October 17-21, 2013 50. α-Synuclein Summit organized by the Michael J Fox Foundation, Nov 7-8th, 2013 New York, USA 51. Bioeconomy Rome International Conference, Rome, No 25-26 52. 6th International Conference on Alzheimer’s Disease and Related Disorders in the Middle East, Istanbul,

Turkey, October 23-24th, 2013 53. 4th Scandinavian Amyloid Symposium, Lund University, Nov 18-20, 2013, Lund, Sweden 54. Brain Forum, Dec 3-4th, 2013, Jeddah, Saudi Arabia

28

2012 55. MRC National Institute for Medical Research, London, UK, February 2nd, 2012 56. Department of Neurobiology, Reed Neurological Research Center, UCLA, LA, USA, March 2nd, 2012. 57. Neuroscience School of Advanced Studies, A course on “Synucleinopathies”, April 17-18th, 2012 58. 2nd Prato Conference on Pore Forming Proteins, Parto, Italy, April 18-20th, 2012 59. CECAM workshop about "Anchoring simulations to experiments: challenges for understanding and

treating Alzheimer's disease", Paris, France, May 14-22nd, 2012 60. Jazan University Research Symposium, Jazan, Saudi Arabia, May 27-28th, 2012 61. Stepping Stone Symposia. “First Conference on Cancer and Neurodegenerative diseases”, Zurich,

Switzerland, June 20-22nd, 2012 62. Department of Chemistry, Technische Universität München, Germany, June 26th, 2012 63. Neurasync training course, Max Plank Institute, Gottengen, Germany, June 26th, 2012 64. 2nd Gordon Research Conference “Intrinsically Disordered Proteins”, Vermont, USA. July 8 – 13, 2012. 65. 5th international Symposium on Macrophage Migration Inhibitory Factor (MIF), Louisville, KY, USA,

Sept 13, 2012 66. '100 Years Lewy Bodies – Where are we now?' a special symposium organized in the historical

building of the Dept of Psychiatry in Munich, Germany, where Friedrich Jacob Heinrich Lewy discovered the Lewy Bodies 100 yrs. ago in 1912. Munich, Germany, September 15th, 2012.

67. Neuromodel Symposium, Kings College London School of Medicine, September 20-21st, 2012 68. School on Biological Physics, Rio de Janeiro, Brazil, September, 30- October 7th, 2012, 69. Post-Translational Modifications: Detection and Physiological Role, Granlibakken, Lake Tahoe,

October 11-14, 2012 70. "Yemen in Transition: Challenges and Opportunities", Harvard University, USA, October 19-21, 2012 71. Scripps Research Institute La Jolla, San Diego, Nov 16th, 2012 72. SASTA-Arab League Conference, Cairo, Egypt, Dec 19-21st, 2012 73. TEDx Sanaá, Sanaá, Yemen, Dec 31st, 2012. 2011 74. Keynote speaker. University of Tokyo, Centre for Medical System Innovation (CMSI) annual

symposium, Tokyo, Japan, Feb 22nd, 2011. 75. 4th international Symposium on Macrophage Migration Inhibitory Factor (MIF), New Haven, USA,

May 11-14th, 2011 76. 10th Congress of the French Neuroscience Society, “ New experimental tools and therapies for

Parkinson’s disease”, Marseille, France, May 25th, 2011 77. International Society of Neuroscience meeting “From genes to pathogenesis: The evolving spectrum of

synucleinopathies”. Athens, Greece, Sep 4-6, 2011. 78. Faculty of Sciences, Jordan University of Science and Technolgoy, Jordan, Oct , 2011 79. King Abdullah University of Science and Technology, Saudi Arabia, Nov 27th, 2011. 2010 80. Boston Biomedical Research Institute, Cambridge, Boston, January 11th, 2010. 81. Alpha Synuclein Summit, Organized by Michael J. Fox Foundation, New York, USA, January 13-14,

2010. 82. Genentech Inc. San Francisco, CA, USA, January 15, 2010 83. Biophysics School on the Molecular Mechanisms of Neurodegeneration Molecular Mechanisms of Neurodegeneration” Venice, Italy, January 25th, 2010. 84. Department of Biochemistry, University of Bologna, Italy, April 20-21st, 2010 85. Global Redesign Summit organized by the World Economic Forum and the foreign ministry of the state

of Qatar. May 21-22nd, 2010. 86. Eli Lily Pharmaceuticals, Indianapolis, USA, July 29th, 2010.

29

87. Parkinson’s Disease Therapeutics Conference organized by the Michael J Fox Foundation and the New York Academy of Sciences, New York, USA. October 6th, 2010.

88. Keynote speaker: Selected by the students to give the keynote lecture at the 1st Instituto de Tecnologia Química e Biológica (ITQB) PhD Students Conference, The New University of Lisbon, October 21-22nd, 2010, Portugal.

89. One of 5 panelist at the Future of Education Summit, session (Closing the GAP), World Economic Forum on the Middle East and North Africa, Marrakech, Morocco, Oct 25-28, 2010

90. α-Synuclein in health and disease 2010, San Diego, USA, November 11-12th, 2010 2009 91. Boehringer Ingelheim Pharma GmbH & Co. KG, January 21-22, 2009 92. Structure of Amyloid Fibrils and Mechanism of their Formation, Halle (Saale), Germany, 8-11

February 2009. 93. Workshop of the International Graduate College “Molecular Complexes of Biomedical Relevance”

Braunschweig, Germany, 25–26 April 2009 94. Conférences Jacques Monod: “Protein folds in infectious and neurodegenerative diseases” Aussois

(Savoie), France, 25-29 April 2009. 95. World Economic Forum on the Middle East, Dead Sea, Jordan, May 15-17, 2009 96. University of Leuven, Faculty of Sciences, Department of Chemistry, Leuven, Belgium, May 27th, 2009 97. 4th European Society of Neurochemistry Conference on “Advances in Molecular Mechanisms of

Neurological Diseaeses”, Mechanisms in synucleinopathies Leipzig, Germany, July 11-14th, 2009. 98. Genentech, San Francisco, CA, June 24th, 2009 99. Eli Lilly, Indiana, June 26th, 2009. 100. FASEB Summer Research Conference on “Amyloid Fibril Formation and Protein Misfolding:

Molecular Mechanisms and Cellular Effects”, Snowmass Village, Colorado, USA. June 28 - July 3, 2009.

101. International Conference of Alzheimer's Disease (ICAD), Featured symposium on "Pathophysiological role of alpha-synuclein in Parkinson's disease and dementia".Vienna, Austria, July 14th, 2009

102. The International Society for Neurochemistry, “Synucleinopathies – mechanisms, models and therapeutic strategies”, Bejing, Aug 29-30, 2009.

103. Japanese-Switzerland Biomolecular Chemistry Symposium, Tokyo, Japan. Sept 11-12th. 104. Seoul National University, Department of Pharmacology, Seoul, South Korea, Sept 14th, 2009. 105. KonkuK University, Department of Biomedical Sciences, Institute of Biomedical Sciences and

Technology, Seoul, South Korea, Sept 16, 2009. 106. Institut de Recherche en Ophtalmologie (IRO), Sion, Switzerland, Sept 22, 2009. 107. Summar School on Dopaminergic Neurons, Trieste, Italy, October 5-6, 2009. 108. 3rd International MIF Symposium, Schloß Hochhausen, Germany, December 3-5, 2009 2008 109. Grand Challenge Speaker, “Institute of Complex Adaptive Matter Annual Conference”, Santa Fe, New

Mexico, January 14-17th, 2008 110. Elan Pharamceuticals, San Francisco, January 13th, 2008 111. 1st International Conference on Drug Design and Discovery, Dubai, UAE, Feb 3-6, 2008. 112. Fassberg lecturer, Max Plank Institute for Biophysical Chemistry, Göttingen, Germany, February 19th,

200 113. Institute De Biologie Structurale et Microbiologie CNRS / IBSM, Marseille, France, March 5th, 2008 114. Annual Meeting of the German Society for Cell Biology, A symposium on Pathologic aggregation of

proteins. Marburg, Germany, March 12-15, 2008 115. Shanghai Medical College of Fudan University, Shanghai, China, March 28th, 2008 Future Medicine, Faculty of Medicine, Alexandria University, Egypt, May 14-16, 2008.

30

116. World Economic Forum (WEF), WEF, Face-to-Face meeting with Global Leadership Fellows, Cologny, Geneva, Switzerland, June 10th, 2008.

117. 6th FENS (Federation of European Neuroscience Societies) Conference: Symposium on Molecular mechanisms in Parkinson¹s disease and other synucleinopathies. 6th FENS, Geneva, Switzerland, July 12-16, 2008

118. α-Synuclein in Health and Disease, Lausanne, Switzerland, September 24-26th, 2008. 119. International Symposium on Medicinal Chemistry (EFMC-ISMC 2008), Vienna, Austria, August 31 –

September 4, 2008 120. Organic Chemistry and Biochemistry Colloquium, Department of Biochemistry, Technical University

of Munich, Germany, October 30th, 2008. 121. Michael J. Fox Foundation for Parkinson’s Research, New York, USA, November 8th, 2008. 122. Merck/Serono, Geneva, Nov 27th, 2008. 123. Institut de Recerca Biomèdica Parc Científic de Barcelona, Barcelona, Spain, December 5th, 2008. 124. New York Academy of Sciences Symposium “"Tau and Beyond: Phosphorylation in

Neurodegenerative Disorders", New York, USA, December 9th, 2008. 125. United Arab Emirates University, Faculty of Medicine Neuroscience Seminar Series, December 23rd,

2008.

2007 126. Keynote Speaker, Lake Geneva Innovation Society (LGIS) Gala Dinner, Geneva, Switzerland, January

23rd. 127. Verbier Neural Workshop. “Nutrition, Exercise and Neurodegenerative Diseases”, January 28-31st,

2007. 128. The Ringber Meeting 2007. “Molecular basis of toxic protein conformation”, Ringberg Castle, Bavaria,

Germany, February 18-21st, 2007. 129. Wyeth Research, Neuroscience Discovery Research, Princeton, New Jersey, USA, March 1-2. 130. Banbury Center, Cold Spring Harbor "When is Amyloid Functional and When is Amyloidogenesis

Pathological? New York, USA, March 11-14th. 131. Third meeting on the "Molecular Mechanisms of Neurodegeneration”, Milan, Italy, May 19-21, 2007. Technical University of Braunschweig, Institute of Biochemistry and Biotechnology, May 23, 2007 132. Keynote Speaker, EndoNeuro meeting: The annual Dutch meeting for molecular and cellular

neuroscience. “Molecular aspects of alpha-synuclein aggregation in Neurodegeneration”, Doorwerth, The Netherland, June 5-8th, 2007

133. University of Twente, Enschede, The Netherlands, June 8, 2007. 134. Plenary speaker, Frontiers in Chemical Biology Symposium, University of Strathclyde, Scotland, UK,

June 16, 2007. 135. Plenary Speaker, New Frontiers in Basic and Clinical Research in Parkinson's disease and other

synucleinopathies Queensland, Australia, July 5-6, 2007. 136. Protein Assembly in Materials, Biology, and Medicine, Direct impact on biological nanosciences,

Crete, Greece, Capsis Hotel, July 7-10. 137. FENS Summer School, Molecular Strategies for treating neurodegenerative diseases, Ofir, Portugal,

July 8-15, 2007. 138. Alpine Meeting “ Molecular basis of disease”, Valens Switzerland, August 16-19th 139. 9th International Conference on Transglutaminases and protein cross linking, Marrakech, Morocco, Sept

1-5, 2007. 140. Max Planck Institute for Biophysical Chemistry, Department of Molecular Biology, Göttingen,

Germany, Oct 23rd 2007. 141. INSERM U679 (former U289) Thérapeutique et Neurologie Expérimentale Hôpital de la Pitié-

Salpêtrière, Nov 9th 2007 142. Biophysics Colloquia, Department of Chemistry, Cambridge University, Cambridge, UK, Nov 30th,

2007.

31

143. Qfirst2007 Doha Conference, Towards Partnership in Research with Arab Expatriate Scientists to Achieve Sustainable Development in Qatar, Doha, December 10-12th, 2007.

2006 144. Novartis Pharmaceuticals, Basel, Switzerland. January 10th, 2006. 145. Biozentrum, University of Basel, January 24th, 2006. 146. Workshop on amyloid formation. The structure of amyloid aggregates, the mechanism of their

formation and the molecular basis of cell dysfunction Firenze, Italy March 25-28, 2006. 147. The annual meeting of the German Society of Human Genetics, "Molecular mechanisms in Huntington

disease protein misfolding", Heidelberg, Germany, March 8, 2006. 148. School of Sciences, Taiz University, Republic of Yemen, April 20th, 2006 149. International Conference “From Sold State to Biophysics III” Dubrovnik, Croatia, June 24-July 1st,

2006. 150. Max Planck Institute for Biophysical Chemistry, Department of Molecular Biology, Göttingen,

Germany, May 21, 2006. 151. Symposium on “Protein Transport, Synaptic Function and Neurodegenerative Diseases”. European

Neuroscience Institute, Göttingen, Germany, Sep 3, 2006. 152. The European BioAlpine Convention, Grenoble- Keynote Speaker, France, October 6, 2006. 153. Department of Theoretical Biology, Peking University, Beijing, China, November 19-21st, 2006. 154. Visiting Professor, Universiti Teknologi Malaysia, Skudai, Johor, Malaysia, November 21-24, 2006. 2005 155. Ph.D. Course in Protein Fibrillation and Aggregation. Aalborg University, Denmark, May 17-20. 156. The Second Japan-Switzerland Workshop on Biomechanics "New Trends in Biomechanics: from

Biomolecule to Tissue. Kyoto, Japan. September 12 -16, 2005. 157. University of Geneva, Department of Biochemistry and Structural Biology Seminar, Geneva, June 17th. 158. The 3rd Lemanic Neuroscience Conference, Diablerets, Switzerland. 159. Nathan Shock Center Conference on Aging: The Role of Protein Misfolding and Aggregation on Aging

and Age-Related Disorders. San Antonio, Texas, October 27-30, 2005. 160. International Neuroscience conference in the United Arab Emirates, November 26-29, 2005. 161. FENS/HERTIE winter school. Neurodegenerative Aggregation Disorders: from genes to protein

aggregation, neuronal dysfunction and experimental treatments. Kitzbuhel, Austria, December 2005. 162. The Second Japan-Switzerland Workshop on Biomechanics "New trends in Biomechanics: from

biomolecule to tissue. Kyoto, Japan. September 12 –16 2004 163. 10th Neural Workshop Verbier, “Molecular, Cellular and Clinical Aspects of Neurodegenerative

Diseases” Verbier, Switzerland, January, 2004. 164. Institute for Complex Adaptive Matter Workshop. Protein Misaggregation: from Biomolecules to

Neurodegeneration. Boston, MA, February 9th- 11, 2004. 165. Washington University School of Medicine, St. Louis, Alzheimer’s disease research center seminar,

April 20th, 2004. 166. Clark University, Department of Chemistry and Biochemistry. Worcester, MA, April 28th, 2004. 167. King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia, April 30th –May 5th. 168. Dutch Endo Neuro Psycho meeting of 2004. Annual meeting for scientists of fundamental and clinical

endocrinology, neuroendocrinology and neuroscience. Amsterdam, Netherlands June 1-3, 2004 169. Netherlands Brain Institute, Amsterdam, Netherlands, June 4th, 2004. 170. Institute de Recerca Biomèdica de Barcelona, Barcelona, Spain, June 10-11th, 2004. 171. The Swiss Federal Institute of Technology (EPFL), Lausanne, Switzerland, June 7th-9th. 172. Summer Neuropeptide 2004 Conference, Miami, July 5-9, 2004.

32

173. Washington University School of Medicine, St. Louis, Department of Biochemistry seminar, July 23th, 2004.

174. FEBS research course "New molecular strategies to treat neurodegenerative diseases". Ofir – Portugal, July 17-23, 2004.

175. University of Texas Health Science Center, San Antonio, Texas. Department of Biochemistry, July 25th, 2004.

2003 176. Boehringer Ingelheim Fonds Internalional Titisee Conferences “Alzheimer’s and Parkinson’s Disease:

From Basic Science to Therapeutic Treatment. Germany, Titise/Black Forest, March 19-23, 2003. 177. Third Multidisciplinary Workshop: “Self-assembling Peptides & Protein Systems in Biology, Medicine

and Engineering” Crete, Greece, August, 2003. 178. Lady Davis Institute for Medical Research, Montreal, Canada, August 27th, 2003. 179. Rensselaer Polytechnic Institute, Department of Chemistry Seminar Series. “Protein fibrillogenesis in

Neurodegenerative Diseases: From Biophysics to Therapeutic Strategies. Albany, NY September 2nd, 2003.

180. University of Rhode Island's Department of Biomedical Sciences, Rhode Island, November 2003. 2002 181. University of California San Francisco, “Physical Properties of Amyloid Diseases”, San Francisco, CA.

December, 25-27 2002 182. Parkinson’s Institute, “Protein Fibrillogenesis in Parkinson’s Disease”, Sunnyvale, CA.December, 28

2002 183. Massachusetts Institute of Technology, Department of Biology: “Structural Biology Seminar”, March,

18, 2002. 184. American Chemical Society National Meeting, “Structural and Mechanistic Aspects of Amyloid Fibril

Formation” Orlando Florida, April, 7-11 2002. 185. FASEB Meeting: “Amyloid and Other Abnormal Protein Processes”, Colorado, June, 15-20 2002. 186. Biogen,Inc, Cambridge, MA, September, 6th, 2002. 187. Protein Folding and Disease: The Horizon Symposia “Protein Folding and Disease” organized by

Nature Publishing Group and Aventis. Verona, Italy, October, 2-5th 2002. 188. Elan BioPharmaceuticals, San Francisco, CA, October 13, 2002. 189. RIKEN Brain Science Institute: The first international workshop of molecular neuropathology

“Frontiers in Molecular Neuropathology” Japan, November, 27-29 2002. 2001 190. King Fahed University of Petroleum and Minerals, Department of Chemistry Seminar, Dhahran, Saudi

Arabia, April, 2001.

33

INDUSTRIAL COLLABORATION/PARTNERSHIPS

Ac Immune (2006 - 2018)

“Dynamics of TDP-43 Aggregation and pathogenesis”

“Elucidating the structural basis of Tau aggregation and Toxicity using a combination of biochemical and cell-based assays”

“Antibody-based therapeutic strategies for treating Alzheimer’s disease”

UCB Pharma SA Belgium (2013 - 2020)

“Elucidating the sequence, molecular and structural basis of alpha synuclein pathology spreading in cellular and animal models of Parkinson’s disease”

“Towards novel imaging agents and antibody based therapies for the diagnosis and treatment of Parkinson’s disease” Under negotiation

Covance (2014 - 2017)

“Development of novel alpha-synuclein antibodies”

Johnson & Johnson (2013 - 2016)

“Photo-modulation as a potential therapeutic strategy for Parkinson’s disease”

Merck Serono (2008 - 2011)

“Modulating α-synuclein phosphorylation as a therapeutic strategy for treating Parkinson’s disease and related disorders”

Nestlé (2007 - 2010)

“An integrative approach to developing diet-based disease preventive treatments for Alzheimer’s disease”

34

FUNDING

Total Third Party Funding Secured Since 2006 = $17.6 Million

35

TEACHING

Courses Taught and Teaching Contribution

BS Master PhD

Term

Contribution in

hrs

Title

Students

No

Total

Credits

Team

Taught

Lead Instructor

2017 12 Neuroscience 1: Molecular Neuroscience and

Neurodegeneration

3 Yes Johannes Graff Bernard Shneider

Hilal Lashuel 2017 28 BIOENG-430: Introduction to

Molecular and Cellular Biotechnology

2 No Hilal Lashuel

2016 12 Neuroscience 1: Molecular Neuroscience and

Neurodegeneration

39

3

Yes

Johannes Graff

Bernard Shneider Hilal Lashuel

2013-2104 6 'Molecular pathology and therapy of neurodegenerative diseases'

14 3 Yes Several Guest Lecturers

2011-2012 52 BIOENG 447: Methods and Tools in Chemical Biology

(Master Course)

15 3 No Hilal Lashuel

2011-2012 52 BIOENG 447: Methods and Tools in Chemical Biology

(Master Course)

12 3 No Hilal Lashuel

2011-2012 6 'Molecular pathology and therapy of neurodegenerative diseases'

(PhD Course)

14 3 Yes Hilal Lashuel Bernard Schneider

2010-2011 52 BIOENG 447: Methods and Tools in Chemical Biology

(Master Course)

3 3 No Hilal Lashuel

Winter 10 6 Molecular Neurobiology & Neurodegenerative diseases

12 3 Yes Darren Moore

28 Biological Chemistry III 82 2 No Hilal Lashuel Summer 10 3 'Molecular pathology and therapy

of neurodegenerative diseases' 10 2 YES Ruth Luthi-Carter

3 Neurogenetics 20 3 Yes Roman Chrast Winter 09 6 Molecular Neurobiology &

Neurodegenerative diseases 12 3 Yes Patrick

Fraering 28 Biological Chemistry III 82 2 No Hilal Lashuel

Summer 09 3 'Molecular pathology and therapy of neurodegenerative diseases'

10 2 YES Ruth Luthi-Carter

Winter 08 6 Molecular Neurobiology & Neurodegenerative diseases

5 3 Yes Patrick Fraering

28 Biological Chemistry III 82 2 No Hilal A. Lashuel Summer 08 3 'Molecular pathology and therapy

of neurodegenerative diseases' 10 2 YES Ruth Luthi-Carter

Winter 07 6 Biological chemistry II 78 2 Yes Willaim Pralong Summer 07 28 Biological Chemistry III 99 2 No Hilal Lashuel

Summer 2007

3 'Molecular pathology and therapy of neurodegenerative diseases'

13 2 YES Ruth Luthi-Carter

36

Winter 6 Methods in Molecular Neuroscience 19 3 YES Patrick Fraering Summer 28 Biological Chemistry III 78 2 No Hilal Lashuel Summer

2006 3 'Molecular pathology and therapy

of neurodegenerative diseases' 12 2 Yes Ruth Luthi-Carter

Winter 2005

6 Molecular Neuroscience 50

6 Yes

Summer 2005

3 'Molecular pathology and therapy of neurodegenerative diseases'

15 2 Yes Ruth Luthi-Carter

Biological Chemistry III (EPFL, 2nd year, B.Sc) The primary objective of this course is to introduce the student to different molecular, biochemical and biophysical approaches for elucidating and modulating the function of proteins in complex biological processes. At the end of the course, the students develop an understanding of how to apply different molecular, biochemical and biophysical tools to i) Elucidate the function of specific proteins in biological processes; ii) Elucidate the role of specific posttranslations modifications on protein function; iii) Study protein-ligand and proteinprotein interactions; iv) Explain the physical and molecular bases of fluorescence spectroscopy; v) Describe different strategies for exploiting autofluorescent proteins, fluorescent tags and molecules to probe protein function in vitro and in vivo; vi) Describe different categories of fusion proteins and understand how to exploit them for functional studies; vii) Describe different techniques and methodologies to probe protein-protein interactions and identify modulators of such interactions; viii) Achieve an overall understanding of classical and chemical genetic approaches to elucidate and modulate protein function. Molecular Neurobiology and Neurodegenerative Diseases (EPFL, 1st year, PhD) The molecular neurobiology and neurodegenerative course, previously called methods in neuroscience, explores the molecular, cellular and neuroanatomical techniques used to develop strategies in the conduct of neuroscience research. First, the information provided by each method, the limitations of each approach, and the expected future developments will be considered. Next, these fundamental and technical aspects of neuroscience will extensively be related to major brain diseases and potential strategies for therapy. Learning outcomes: (1) knowing and understanding the subject matter of the course, (2) developing critical, analytical, synthesizing and problem-solving skills, (3) increasing students’ reading ability and communication skills. Bio705-Molecular Pathology and Therapy of Neurodegenerative Diseases (EPFL, PhD) The primary objective of the course is to introduce the student to the processes of Neurodegeneration in the CNS and the potential therapies envisaged today and tomorrow to ameliorate of cure neurodegenerative diseases in the CNS. The course focuses on 1) The latest discoveries on the molecular pathology of Parkinson's, Hungtington's, Alzheimer's diseases and Amyotrophic lateral sclerosis will be presented; 2) Emphasis will be given to the genetic aspects of each disease, i.e. the concepts of negative gain of function of mutated proteins, the role of aggregatopathy and specificity of the pathogenesis of each disease will be discussed as well of the consequences of a particular disease (Hungtington's disease) on the functional genomics of the affected tissue; 3) The potential therapeutic approaches, including the delivery of neurotrophic factors, gene therapy and the use of stem cells for brain repair will be discussed; 4) Concepts such as apoptosis and necrosis in the CNS will be presented; 5) New technological approaches to unravel the sequence of events of neurodegenerative. BIOENG-477- Chemical Biology: Tools and Methods (EPFL Master). The primary objective of this course is to teach the student how to apply and integrate different chemical, biochemical and cellular tools and approaches to answer fundamental questions in biology and elucidate the molecular functions of proteins in health and disease.

37

BIOENG-430- Itroduction to Molecular and Cellular Biotechnology: The course presents comparatively several topics at the interface between bioengineering and chemical engineering. This course reviews the various facets of contemporary biotechnology. Numerous examples of applications related to medicine, the pharma industry, agriculture, and environmental issues will be presented.

38

SERVICE AND PROFESSIONAL ACTIVITIES

Service to the field

Ad hoc reviewer for several scientific journals, including ACS Chemical Biology, Analytical Biochemistry, Amyloid, Biochemistry, Biophysical J, Biopolymers, Cell Biochemistry and Biophysics, Chemistry and Biology, Journal of Biological chemistry, Journal of the American Chemical Society, European Journal of Neuroscience, FEBS Letters, FASEB J, Human Molecular Genetics, Journal of Molecular Biology, Journal of Neurochemistry, Journal of the American Chemical Society , Laboratory Investigations, Molecular Pharmacology, Nature Medicine, Nature Methods, Nature Reviews, Nature Structural and Molecular Biology, Parkinson’s disease, Protein Science, Proceeding for the National Academy of Science.

Ad hoc reviewer of Grant Applications Michael J. Fox Foundation (2009 - present) http://www.michaeljfox.org/ Swiss National Science Foundation http://www.snf.ch Medical Research Council, UK https://www.eaa.mrc.ac.uk/EAA/ Alzheimer’s Association http://www.alz.org/ Helmholtz Association http://www.helmholtz.de/ Qatar National Research Fund http://www.qnrf.org/ Netherlands Org. for Scientific Research (NWO) http://www.nwo.nl/nwohome.nsf Medical Research Council (UK) http://www.mrc.ac.uk/index.htm The Knut and Alice Wallenberg Foundation http://www.wallenberg.com/kaw/in_english/ Deutsche Forschungsgemeinschaft (DFG) (Collaborative Research Centers) http://www.dfg.de European Research Council (ERC) https://erc.europa.eu/

Editorial Boards 2011 - Member, Editorial board of ChemBiochem 2008 - Associate Editor, Frontiers in Molecular Neuroscience 2007 - 2010 Member, Academic Editorial Board of PLoS ONE (http://www.plosone.org)

International Committees and Services 1. Member, Board of Governance of the Institute for Complex Adaptive Matter (ICAM-I2CAM)

http://www.i2cam.org/. 2008 2. Member, First Arab Scientists Conference Follow up and Advisory Committee to Qatar Foundation

and Her Highness Sheika Mozza bint Nasser al-Misnid, Wife of the Emire of Qatar (2006-2009) http://www.qf-qfirst.info/

3. Member, Advisory board, Yemeni Scientific Research Foundation, 2004-present 4. Co-founder and secretary general of the Society for Advancing Science and Technology in the Arab

World. http://sastaworld.com 5. Co-founder and Co-director, American Association of Yemeni Scientists and Professionals,

www.aaysp.org 6. Founding member of the International Brain Organization MENA subregion. An IBRO-affiliated

organization focusing on promoting neuroscience research in the MENA region

39

International Panels and Working Groups 1. Sept 26-27th, 2016 : Participated, as member of an international experts panel, in a two-days onsite

visit organized by the German Research Foundation (DFG) to reviwe a proposal for establishing a Clinical Research Unit at Ulm University. This was a review of a mulitinvestigator research unit focusing on “Propagation of neurodegenerative diseases - modifiers and mechanisms”

2. September 2013 –January 2014. Served as a member of a special basic science working group composed of 12 thought leaders charged with creating a roadmap for Basic Science research in Parkinson’s disease, that recognizes the advances that have been made and identifies the challenges and roadblocks the field faces in moving forward. The group was charged with developing a prioritized list of twelve recommendations that were presented and discussed at the workshop that was organized by National Institute of Neurological Disorders and Stroke (NINDS), “Research Challenges and Opportunities for Parkinson’s Disease” and held at NIH on January 6-7th, 2014. This workshop is intended to develop recommendations for research priorities over the next five years in Basic Science, Translational, and Clinical research in Parkinson’s Disease to help guide NINDS and the NIH in programmatic planning going forward. We only have this meeting every several years, and the recommendations from this meeting are taken extremely seriously by NINDS as we develop our PD research programs going forward. onlinelibrary.wiley.com/doi/10.1002/ana.24261/abstract;jsessionid=029282FA102D31D4F0965A4D0494C14E.f04t03

3. May 15-16th, 2012 : Participated as a member of an international experts panel, established by the German Research Foundation (DFG) to review a multi-investigator proposal on the establishment of Collaborative Research Centre (CRC) 1080 “Molecular and Cellular Mechanisms of Neural Homeostasis“

International Schools and Advanced Training Programs 1. Co-Lead organizer, International Brain Organization (IBRO-MENA) Neuroscience School in

Neurodegenerative and Neurodevelopmental Disorders, Qatar, Doha, Nov 19-22, 2015). 2. Co-founder and Co-organizer of the first Cancer Biology and Therapeutics Program (HMS-CBT) as

a joint initiative of the Harvard Medical School Office of Global Education and the Qatar Biomedical Research Institute (QBRI). HMS-CBT was launched in 2015 a 12-month blended-learning program (hms.harvard.edu/cbt) designed to provide participants with deep knowledge of the cancer biology that shapes modern preventive and therapeutic approaches.

3. Lead organizer of a one week advanced course on “Protein Misfolding and Accumulation; From Cellular Mechanisms to Imaging and Therapeutic Strategies” as part of the Neuroscience School of Advanced Studies Abbazia di Novacella, Südtirol, Italian Alps August 22 - 29 , 2015.

4. Co- organizer, International Brain Organization (IBRO-MENA) Neuroscience School in Epilepsy: From Pathophysiology to Diagnosis and Therapy, Qatar, Doha, Dec 19-22, 2015.

5. Co-Lead organizer, International Brain Organization (IBRO-MENA) Neuroscience School in Neurogenetics: Genetic Basis of Neurologic and Psychiatric Diseases, Qatar, Doha, Dec 10-15, 2014

Organizatin of Scientific meetings and conferences 1. Co-lead organizer of the Islet Cell Transplantation Symposium, Doha, Qatr, Janury 14th, 2017 2. Co-Chair: 3rd Middle East Molecular Biology Society Meeting, Doha, Qatar, Nov 14-17, 2016 3. Co-organizer, International Brain Organization (IBRO-MENA) Annual Research Symposium, Qatar,

Doha, Nov 16-19, 2016 4. Chair and organizer of a special session on “Biomedical and Health Research in

Qatar: Transforming Challenges into Competitive Advantages and Economic Opportunities”During the Qatar Research and Development Annual Research Forum, March 22-23rd, 2016

40

5. Lead organizer, International Brain Organization (IBRO-MENA) Neuroscience School and Research Symposium, Qatar, Doha, Nov 16-22, 2015

6. Lead organizer, International Brain Organization (IBRO) Neuroscience School and Research Symposium, Qatar, Doha, December 10-17, 2014

7. Co-Chair- The Brain Forum 2014 8. Co-organizer, Human Genome and Personalized Medicine, Doha, Qatar, June 10, 2014 9. Lead organizer, The Brain Forum, 2013, http://thebrainforum.org 10. Co-Organizer, “When Arab Minds Integrate” a conference organized by the Arab League and the

Society of Advancing Science and Technology in the Arab World. Egypt, Cairo, Dec 18-20, 2012 11. Co-Organizer, 1st IBRO-MENA Neuroscience School on Neurogenetics, Tunis, Tunis, Oct 2012 12. Co-Organizer, 1st IBRO-MENA Neuroscience Conference and School, UAE, Al- 7-9th, 2011 13. Member, organizing committee. IBRO Middle East Neuroscience School and Conference, UAE, Al-

Ain Jan 31st – Feb 5th, 2011. 14. Chair, First Conference on α-Synuclein “α-Synuclein in Health and Disease” Lausanne, Switzerland,

August 17-19, 2008. http://fens2008.neurosciences.asso.fr/pages/symp.html 15. Chair, Symposium on Molecular mechanisms in Parkinson¹s disease and other synucleinopathies. 6th

FENS (Forum of European Neuroscience), Geneva, Switzerland, July 12-16, 2008. http://fens2008.neurosciences.asso.fr/pages/symp.html

16. Member, Organizing committee, 2008 USGEB (Union of the Swiss societies for experimental biology) conference. New landscapes of life sciences: Engineering meets Biology. EPFL, February 6-7th, 2008. http://usgeb2008.epfl.ch/

17. Co-chair & Member, Organizing committee of the first Qatar University Life Sciences Symposium “Diabetes, Genetics, Environmental Factors and Therapeutic Strategies”, Qatar University, Doha, Qatar December, 13th 2007. http://www.qu.edu.qa/conferences/QULSS/

18. Member, Organizing committee of the Qfirst 2007 Arab Scientists Conference, Doha, Qatar December, 2007.

19. Chair, organizing committee, Swiss Proteomic Society Conference “Proteomics: Pushing the limits” Lausanne, Dec 3-5th, 2007. http://sps07.swissproteomicsociety.org/info/organisation?start=2

20. Member, organizing committee of the Life Science Symposium 2007, Lausanne, Switzerland, October 2007. http://lss07.epfl.ch/

21. Member, the International Advisory Committee for the Protein Assembly in Materials, Biology, and Medicine, Direct impact on biological nanosciences, Crete, Greece, Capsis Hotel, July 7-10, 2007.

22. Member, International advisory board, New Frontiers Symposium “Basic and Clinical Research in Parkinson's disease and other synucleinopathies” Queensland, Australia, July 5-6, 2007.

23. Member, Organizing committee of the Lemanic-Neurosciences Annual Meeting, Diablerets, Switzerland, September 8-9th, 2006.

24. Member, International advisory board, International Symposium on Bio-Inspired Computing, Sept 5-7. 2005.

25. Chair and Co-organizer, The First International Institute for complex adaptive matter (I2CAM) exploratory workshop on protein aggregation and amyloid formation in systemic and neurodegenerative diseases: Physical, Molecular and Biological Apporaches. Lausanne, Switzerland, July 16-19, 2005. http://www.i2cam.org/archive.php

41

Thesis Committes

Thesis Director:

Lastname Name Immatriculation

date Exmatriculation

date Ait Bouziad Nadine 15.10.2012 30.04.2017 Altay Melek Firat 31.10.2016 2020 Ansaloni Annalisa 27.08.2009 07.05.2014 Chiki Anass 01.09.2015 2019 Desobry Carole 16.09.2010 10.12.2014 El Turk Farah 07.10.2005 19.03.2010 Fares Mohamed Bilal 12.10.2010 21.08.2015 Fauvet Bruno Claude Daniel 12.08.2009 07.05.2014 Hejjaoui Mirva 09.10.2008 28.09.2012 Jan Qureshi Mohammad Asad 26.07.2006 05.08.2010 Mbefo Kamdem Martial 12.08.2009 07.05.2014 Ouertatani-Sakouhi Hajer 22.12.2005 12.04.2010 Vercruysse Filip 12.10.2009 14.07.2014 Viertl David 16.06.2005 04.08.2006 Vieweg Sophie 06.02.2013 31.01.2017

Thesis Co-Director:

Lastname Name Immatriculation

date Exmatriculation

date Benmessaoud Ryma Iness 13.03.2012 Cendrowska Urszula Beata 15.08.2015

President of jury

Lastname Name Exmatriculation

date Degiacomi Matteo Thomas 04.07.2012 Ramaswamy Srikanth 20.12.2011 Tomm Christian 29.03.2012

42

Member of jury

Lastname Name Exmatriculation

date Azeredo da Silveira Lajaunias Samareh 26.05.2008 Azzabi Zouraq Fahd 12.03.2008 Gökce Ozgün 20.05.2009 Iacovache Mircea Ioan 14.03.2011 Jacob Silva Paulo Henrique 24.06.2016 Nuhn Harald 17.11.2008 Pino Emilda 21.02.2012 Ruggeri Francesco Simone 03.06.2015

43

Training and Mentoring of Students, Post-docs and Employees

Hilal A. Lashuel, PhD

44

PhD Students

Name Degree Previous institution

Theses Title Grad. date

Duration LMNN

Current position

Current institution

Mohamed-Bilal Fares

MSc American University of Beirut, Lebanon

Recapitulating De Novo Alpha-Synuclein Fibrillization in a Novel Neuronal Model of Parkinson's Disease THÈSE NO 6679 (2015)

09/2010 08/2015

Post-doctoral researcher 2015-present

Brain-Mind Institute Lashuel Laboratory EPFL, Lausanne, Switzerland

Carole Desobry

MSc EPFL, Lausanne, Switzerland

Reversible attachment of Cell-Penetrating Peptides for the efficient delivery of α-synuclein to HeLa cells and primary cortical neurons THÈSE NO 6412 (2014) 05.12.2014

10/2010 09/2014

Senior Research Officer

Glenmark Pharmaceuticals, Switzerland

Annalisa Ansaloni

MSc University of Modena, Italy

Elucidating the role of N-terminal phosphorylation in regulating the structure and the aggregation propensities of Huntingtin exon 1 using a semisynthetic strategy THÈSE NO 6188 (2014)

09/2009 08/2013

Research intern

Centre Hospitalier Universitaire Vaudois, Switzerland

Bruno Fauvet

MSc EPFL, Masterstudent

Protein semisynthesis and total synthesis approaches to elucidate the role of Alpha-Synuclein post-translational modifications THÈSE NO 6187 (2014)

08/2009 08/2013

Post-doctoral fellow

University of Lausanne, Switzerland

Martial Mbefo Kamdem

MSc University of Lausanne, Switzerland

The Role of S129 Phosphorylation in Regulating the Cellular Properties and Secretion of Alpha-Synuclein: Implication for alpha-synuclein function in health and disease THÈSE NO 6110 (2014)

08/2009 08/2013

Scientist in Oculogenetic and Gene Therapy

Hôpital Ophtalmique Jules-Gonin, Switzerland

Filip Vercruysse

MSc Ghent University,

The role of fibril formation and growth in

07/2009 09/2013

Visiting researcher

Bernstein institute for neuroscience in

45

Belgium a-synuclein mediated extracellular toxicity THÈSE NO 6106 (2014)

Berlin, Germany

Mirva Hejjaoui

MSc Ecole nationale Supérieure de Chimie de Montpellier, France

Elucidating the role of post-translational modifications of alpha-synuclein using semisynthesis: phosphorylation at Tyrosine 125 and monoubiquitination at Lysine 6 THÈSE NO 5494 (2012)

10/2008 09/2012

Technology transfer project manager 2015-2016 Biological Assessment Technologies Manager 2013-2015

Genzyme, France Syngenta Corp Protection

Hajer Ouertatani Sakouhi

MSc Universty of Neuchâtel & EPFL, Laboratory of Cellular Biotech., Switzerland

Small Molecule Based Approaches to Inhibit Macrophage Migration Inhibitory Factor (MIF) Activities and Elucidate its Role in Health and Disease THÈSE NO 4633 (2010)

12/2005 08/2010

Post-doctoral fellow

University of Geneva, Switzerland Dpt of Cell Physiology and Metabolism

Asad Qureshi

MD EPFL, Lab of Neural Micro Circuitry, Switzerland

Nucleation Dependent Polymerization of Amyloid-ß (Aß) as an Important Determinant of Aß Amyloid Formation and Neurotoxicity - Implications for the Pathogenesis of Alzheimer’s Disease and Design of Therapies THÈSE NO 4773 (2010)

10/2005 07/2010

Post-doctoral fellow Post-doctoral fellow

University of British Columbia, Vancouver, Canada Michael Hayden Group-2012-2013 Department of Pathology, BC Cancer Research Centre/2014-current

Farah El-Turk

MSc Ecole nationale Supérieure de Chimie de Montpellier, France

Elucidating the Role of Quaternary Structure in Modulating Macrophage Migration Inhibitory Factor (MIF) Functions THÈSE NO 4632 (2010) Recipient of two

10/2005 03/2010

Post-doctoral researcher 2012 - present Visiting Scholar 2013 – present

Cambridge University, UK Department of Chemistry & McGail University, Canada

46

prestigious fellowship from the National Science Foundation (Prospective Advance researcher Fellowship) 2010-2012 & 2012-2014

47

Post-doctoral Fellows Name Degree Previous

Institution Previous position

Duration LMNN

Current Postion

Current institution (2016)

Sean Deguire

PhD Vanderbilt Institute Chemical Biology, USA

PhD Student

03/2012 06/2016

Chemical Specialist

Intellectiual property in a law firm, Washington DC

Ritwik Burai PhD PhD 01/2012 08/2016

Scientist AC Immune, Switzerland

Mark Baillie

PhD Emory University PhD student

/2012 /2013

Assistant Professor of Chemistry& Biochemistry

University of Delaware, USA

Mohamed-Bilal Fares

PhD LMNN, EPFL, Switzerland

PhD Student

09/2010 08/2016

Postdoc LMNN,EPFL, Switzerland

Loay Awad PhD Ludwig Institute for Cancer Research, Switzerland

Postdoc 10/2009 09/2010

Assistant Professor

University of Dammam Department of Chemistry Saudia Arabia

Zheming Wang PhD Max-Planck- Institute Molecular Physiology, Germany

PhD Student

10/2009 09/2010

Chief Executive Officer

BSAZ (hangzhou) Biotech Co. Ltd. China

Michel Prudent PhD EPFL, Lab of Physical & Analytical Electrochemistry, Switzerland

PhD Student

06/2009 – 05/2010

Director Blood Products Research Laboratory at Transfusion Interrégionale CRS SA Switzerland

Margot Fournier PhD INSERM U679, University Paris V France

PhD Student

01/2009 12/2010

Postdoc University Hospital of Lausanne Switzerland

Sara Butterfield PhD University of Geneva, Switzerland

Postdoc 10/2008 – 08/2010

Patent Consultant

Stonemason Law Patent Group

Abid Oueslati PhD CNRS, Lab IBDML, France

PhD Student

07/2008 04/2010

Assistant Professor

Québec-Université Laval Department of Molecular Medicine Canada

Diana Olschewski PhD Max-Plank-Institute of Molecula Physiology,

Postdoc 05/2008 – 06/2009

Project Manager

Haupt Pharma Germany

48

Dortmund, Germany

Saviana DiGiovanni

PhD University of Geneva School of Pharmaceutical Sciences, Switzerland

PhD Student

10/2007 – 11/2009

Pharmacist, PhD Naturopath and Nutritional Counselor

Medical Practice, Nice France

Tristan Bolmont PhD University of Basel, Switzerland

PhD Student

10/2007 – 10/2008

Chief Scientist

Stemedica International, Switzerland

Valerie Grimminger

PhD Technische Universität Munich Department of Biotech Germany

PhD Student

06/2007 – 10/2010

Innovation and Development Project Manager

Nestlé S.A, Lausanne Switzerland

Lionel Terzi PhD University of Geneva, Switzerland

Research Associate

03/2006 – 09/2006

Clinical Database Manager

Covance Switzerland

Katerini Paleologou

PhD Lancaster University, Department of Biological Sciences, U.K.

PhD Student

07/2005 – 07/2009

Assistant Professor

Democritus University of Thrace Department of Molecular Biology and Genetics Alexandroupolis, Greece

Adrian Schmid PhD University College of Dublin, Ireland

PhD Student

04/2005 – 10/2007

Collaborateur scientifique

EPFL Proteomic Core Facility Switzerland

Master Students Name Degree Previous

Institution Duration LMNN

Postion in LMNN

Current institution (2016)

Chibani Samah MS EPFL SV

02/2014 08/2014

Master Student

Gizem Zorludemir

MS EPFL SV

02/2013 08/2013

Master Student

Lonza Biotechnologie

Monique Montavon

MS EPFL SB

/2013 /2014

Master Student

Regulatory Affairs Intern Shire

Nadia Gerweck MS EPFL SV

10/2012 – 07/2013

Master Student

EPFL, Scientific Collaborator

Anass Chiki MS

EPFL SV

10/2012 – 10/2013

Master Student

EPFL, PhD Student

49

Nino Jejelava MS EPFL SV

07/2009 – 07/2011

Master Student

University of Zurich PhD Student

Jonas Fuks MS

University College of Dublin, Ireland

06/2009 07/2009

Master Student

Department of Molecular Biosciences, The Wenner-Gren Institute

Véronique Vocat MS EPFL SV

03/2006 – 09/2006

Master Student

University of Berne PhD Student

Staff Name Previous Institution Previous

position Duration LMNN

Postion in LMNN

Current institution (2016)

Céline Vocat EPFL Switzerland

RA 02/2012 11/2015

Laboratory Assistant

John Perrin CHUV Switzerland

RA 11/2012 – 09/2013

Laboratory Assistant

University of Lausanne

Verene Pignat EPFL Switzerland

RA 06/2009 07/2009

Research Assistant

University of Lausanne

Nathalie Jordan ISREC Switzerland

RA 07/2007 – 08/2015

Laboratory Assistant

EPFL

Visiting Scholars (PhD students and Post-doctoral Fellows) Name Institution Period Luís Miguel Oliveira Instituto Superior de Ciências da Saúde

Egas Moniz

02/2009 - 04/2009

Simona Carmen Eleuteri University of Bologna, Italy

11/2008 - 07/2009

Ronit Shaltiel Tel-Aviv University, Israel

10/2008 - 11/2008

Muriel Arimon University of Barcelona , Spain

09/2007 - 01/2008

Prof. Hamda Al-Naemi Dept of Biol. Sciences, Qatar Uni.

07/2007 - 08/2007

Alessandra Chesi Lab. of Neurobiology, International School for Advanced Studies, Italy

09/2006 - 12/2006

Saviana Di Giovanni Department of Pharmaceutical Sciences

08/2006 - 01/2007

Sidhartha Chafekar Neurogenetics Laboratory Academic Medical Centre, Netherland

03/2005 - 06/2006

50

Undergraduate Students

Name Institution Period Eve Rahbe EPFL

02/2016 - 06/2016

Ravikumar Priyanka EPFL, School of Life Sciences /2014 - /2015

Vivien Gaillet EPFL

02/2014 - 06/2014

Nobumasa Takao Tokyo Institute of Technology Japan

08/2010 - 09/2010

Nobumasa Takao Tokyo Institute of Technology Japan

08/2010 - 09/2010

Oke Isdin McGill University Canada

07/2010 - 08/2010

Ayah Khubieh

EPFL 22/10/2009 - 15/11/2009

Ghada Al Mahmoud Qatar University Qatar

01/08/2009 - 31/08/2009

Jenny Zhang Hong Kong University Hong Kong

01/07/2009 - 31/08/2009

Keshav Krishnamani

EPFL-School of Life Sciences 07/25/2008 - 09/2008

Yan Tan Peking University China

07/01/2008 - 09/2008

Rizan Sheta University of British Columbia Canada

07/01/2008 - 09/2008

Benjamin Simone

EPFL-School of Life Sciences 01/15/2008 - 08/2008

Ivan Hang Summer Scholar Croatia

07/14/2007 - 09/2007

Jue Wang Harvard University, USA

06/14/2007 - 09/2007

Radhakrishnan P. N. MRDG, Indian Institute of Science India

05/15/2007 - 12/2007

Stephanie Metzger

EPFL- School of Life Sciences 07/01/2007 - 12/2007

Ayat Mourad

EPFL- School of Life Sciences 07/01/2007 - 09/2007

Xiao Annie Wang Harvard University USA

06/08/2006 - 08/18/2006

Ekaterina Ananievskaia University of Geneva, Switzerland

03/13/2006 - 07/07/2006

Mirva Hejjaoui Ecole Nationale Supérieure de Chimie de Montpellier, France

07/01/2006 - 09/03/2006

Keshav Krishnamani

EPFL 04/01/2006 - 07/01/2006

Alexandra Fragnière EPFL 04/01/2006 - 07/01/2006